<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206409</article-id><article-id pub-id-type="doi">10.1101/2025.06.10.658805</article-id><article-id pub-id-type="archive">PPR1034108</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Neural crest induction requires SALL4-mediated BAF recruitment to lineage specific enhancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Demurtas</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barnada</surname><given-names>Samantha M.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Domselaar</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mitchell</surname><given-names>Zoe H.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deelen</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Trizzino</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Life Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label>Department of Biochemistry and Molecular Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ysqcn41</institution-id><institution>Thomas Jefferson University</institution></institution-wrap>, <city>Philadelphia</city>, <state>PA</state>, <country country="US">USA</country></aff><author-notes><corresp id="CR1">
<label>*</label>Lead contact: <email>m.trizzino@imperial.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>10</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><title>Summary</title><p id="P1">Neural crest induction begins early during neural plate formation, requiring precise transcriptional control to activate lineage-specific enhancers. Here, we demonstrate that SALL4, a transcription factor strongly expressed in cranial neural crest cells (CNCCs) and associated with syndromes featuring craniofacial anomalies, plays a critical role in this early regulatory process. Using a <italic>SALL4</italic>-haploinsufficient human iPSC model that recapitulates clinical haploinsufficiency, we show that the SALL4A isoform directly interacts with the BAF complex subunit DPF2 through its zinc-finger-3 domain. This interaction enables SALL4-mediated recruitment of BAF to CNCC-specific enhancers during early neural plate stages. Without functional SALL4, BAF fails to load at chromatin, leaving CNCC enhancers inaccessible despite normal neuroectodermal progression. Consequently, cells cannot undergo proper CNCC induction and specification due to persistent enhancer repression. Our findings reveal SALL4 as an essential regulator of BAF-dependent enhancer activation during early neural crest development, providing molecular insights into SALL4-associated craniofacial anomalies.</p></abstract><kwd-group><kwd>SALL4</kwd><kwd>DPF2</kwd><kwd>SALL4A</kwd><kwd>BAF</kwd><kwd>neural crest</kwd><kwd>enhancers</kwd><kwd>chromatin accessibility</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Embryonic development is a tightly regulated process that depends on the ability of pluripotent embryonic stem cells (ESCs) to progressively acquire specialized fates and functions<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. This enables their differentiation into a diverse range of somatic lineages, ultimately giving rise to a complex, fully integrated organism from a single cell<sup><xref ref-type="bibr" rid="R2">2</xref></sup>. These diverse cell identities are established through epigenetic mechanisms that regulate the spatiotemporal expression of lineage-specific gene regulatory networks, primarily by modulating chromatin accessibility. Chromatin states range from open to closed, shaped by a combination of epigenetic modifications, including histone methylation and acetylation, incorporation of histone variants, DNA methylation, and the activity of chromatin remodeling complexes. These large, multi-subunit complexes utilize ATP hydrolysis to reposition nucleosomes, dynamically regulating access to genes and their regulatory elements<sup><xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R6">6</xref></sup>.</p><p id="P3">Transcription factors also play a crucial role in cell fate determination, acting as molecular switches that trigger mechanisms that ultimately activate or repress genes as a result to their binding to specific regulatory DNA sequences within <italic>cis</italic>-regulatory elements. They influence gene expression by recruiting or inhibiting the transcriptional machinery and regulating 3D chromatin organization<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R9">9</xref></sup>. Among these, the embryonic C2H2 zinc-finger transcription factor SALL4 is involved in a wide range of developmental processes<sup><xref ref-type="bibr" rid="R10">10</xref></sup>. SALL4 is highly expressed in pluripotent cells and throughout embryonic development, gradually decreasing after birth to become undetectable in adult tissues<sup><xref ref-type="bibr" rid="R11">11</xref></sup>.</p><p id="P4">In humans, the SALL4 gene produces two main isoforms through alternative splicing: SALL4A (1053 aa) and SALL4B (617 aa), which have been proposed to play distinct roles in ESCs. Namely, Rao et al.<sup><xref ref-type="bibr" rid="R12">12</xref></sup> suggested that SALL4B has function limited to pluripotency regulation in ESCs, while SALL4A is the isoform primarily active during development. Although SALL4 is expressed as early as the two-cell stage, its role in maintaining pluripotency remains debated. Some studies suggest that SALL4 cooperates with core pluripotency transcription factors, such as OCT4 and NANOG, to sustain stem cell identity<sup><xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref></sup>. In contrast, other studies propose that SALL4 plays a more marginal role in directly regulating the pluripotency gene regulatory network<sup><xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup>.</p><p id="P5">During early mouse development, <italic>Sall4</italic> is broadly expressed throughout the embryo, however, as gastrulation progresses, its expression becomes more posteriorly restricted, localizing primarily to the developing tail bud and limb buds<sup><xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R19">19</xref></sup>. Here, it regulates the cell fate commitment of neuromesodermal progenitors by suppressing the neural gene regulatory network in mesodermal cells while simultaneously enhancing mesodermal gene expression<sup><xref ref-type="bibr" rid="R20">20</xref></sup>. Additionally, Sall4 remains expressed in mouse craniofacial regions until the E9.5 stage, including the developing frontonasal process as well as the mandibular and maxillary arches<sup><xref ref-type="bibr" rid="R18">18</xref></sup>. These craniofacial structures originate from cranial neural crest cells (CNCCs), a subpopulation of neural crest cells that migrate dorsolaterally to give rise to the cartilage and bones of the face and anterior skull, as well as cranial neurons and glia. Consistent with this, individuals with <italic>SALL4</italic> haploinsufficiency exhibit a range of phenotypes, including distinctive facial features such as epicanthal folds, widely spaced eyes, and a depressed nasal bridge, along with cranial nerve-related conditions. These include Duane anomaly, a congenital strabismus resulting from abnormal oculomotor nerve innervation<sup><xref ref-type="bibr" rid="R21">21</xref></sup>, and sensorineural hearing loss<sup><xref ref-type="bibr" rid="R22">22</xref></sup>.</p><p id="P6">Together, these findings suggest that SALL4 may play a critical role in CNCC induction, specification and differentiation. However, its involvement in this developmental process has not yet been investigated. Previous studies have also suggested that SALL4 interacts directly with chromatin remodeling complexes. For example, several studies in mice have identified Sall4 as an interactor of the NuRD chromatin remodeling complex, in both embryonic cells and various developmental processes<sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R26">26</xref></sup>. Additionally, recent mass-spectrometry experiments conducted by our group in early stages of human iPSC-to-CNCC differentiation, and specifically at the neuroectodermal stage, revealed that SALL4 interacts with the BAF chromatin remodeling complex during this developmental process<sup><xref ref-type="bibr" rid="R27">27</xref></sup>.</p><p id="P7">Since this was the first report of a potential direct SALL4-BAF interaction, here we set out to investigate the scope of this interaction, and to determine the role of SALL4 during cranial neural crest cell specification. Given that human SALL4-associated developmental syndromes result from <italic>SALL4</italic> haploinsufficiency, we generated a <italic>SALL4</italic> heterozygous human iPSC line using CRISPR-Cas9-mediated deletion. With this approach, we demonstrate that, at early stages of CNCC specification, SALL4 is required for the recruitment of the BAF complex to open the chromatin to enhancers essential for CNCC fate. In the absence of SALL4, cells progress normally through the neuroectodermal stage but fail to specify into CNCCs, as the lineage-specific enhancers remain repressed. Finally, using <italic>in silico</italic> approaches, we predict that SALL4A isoform directly interacts with the BAF subunit DPF2. Specifically, this interaction occurs between the zinc-finger-cluster-3 (ZFC3) domain of SALL4A and the plant homeodomains (PHDs) of DPF2.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>SALL4 interacts with the BAF complex</title><p id="P8">Cranial neural crest cells can be generate <italic>in vitro</italic> starting from human pluripotent stem cells (hiPSCs). This protocol is approximately two weeks long, and it first goes through a neuroectoderm intermediate <sup><xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R31">31</xref></sup>. In our previous work<sup><xref ref-type="bibr" rid="R27">27</xref></sup>, mass spectrometry (IP-MS) conducted at early stages of the iPSC-to-CNCC differentiation protocol, and specifically Day-5, which corresponds to the neuroectodermal stage, revealed that SALL4 interacts with the BAF chromatin remodeling complex in this developmental cell population. Since this was the first report of a SALL4-BAF interaction, we performed a co-immunoprecipitation (co-IP) at Day-5 to validate it. Specifically, we performed pull-down of ARID1B, which is the only ARID1 subunit active and incorporated in BAF at this stage <sup><xref ref-type="bibr" rid="R27">27</xref></sup>, and blotted for SALL4. This co-IP confirmed that ARID1B interacts with both SALL4 isoforms at this time-point (<xref ref-type="fig" rid="F1">Fig. 1A</xref>).</p><p id="P9">The BAF chromatin remodeling complex is a multi-subunit assembly composed of a dozen components, which are differentially incorporated in a tissue-specific manner<sup><xref ref-type="bibr" rid="R32">32</xref></sup>. Based on which subunit is present in each complex, in mammals these can be classified into canonical BAF, polybromo-associated BAF, and non-canonical BAF<sup><xref ref-type="bibr" rid="R33">33</xref></sup>. While our mass-spec and co-IP experiments support the interaction between SALL4 and the canonical BAF (ARID1B is not incorporated in the other BAF configurations), neither of these two approaches has the resolution to identify the exact BAF subunit that mediates the interaction with SALL4. Therefore, we performed an <italic>in silico</italic> analysis using AlphaFold3<sup><xref ref-type="bibr" rid="R34">34</xref></sup>. We tested various BAF subunit combinations along with four histones and an AT-rich DNA sequence which has been empirically shown to be recognized by SALL4 (5’-GGAAATATTACC-3’, PBD: 8A4I). The output was statistically significant, with a 0.45 predicted template modeling (pTM) score and 0.47 interface predicted template modeling (ipTM) score. Through this approach, AlphaFold3 predicted a direct interaction between DPF2, a broadly expressed BAF subunit, and the zinc-fingers 5 and 6 (ZFC3) and 7 (ZFC4) of SALL4 (<xref ref-type="fig" rid="F1">Figs. 1B, 1C, 1D</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>). <italic>DPF2</italic> is a member of the <italic>BAF45</italic> gene family, which also includes <italic>PHF10, DPF1</italic>, and <italic>DPF3</italic>. We were able to rule out its paralogues based on their distinct expression patterns, incorporation into specific BAF complexes, and previous reports that BAF45 subunits are not functionally redundant<sup><xref ref-type="bibr" rid="R35">35</xref></sup>. In particular, PHF10 is exclusively associated with the pBAF complex, which does not incorporate ARID1B<sup><xref ref-type="bibr" rid="R36">36</xref></sup>, while DPF1 and DPF3 are specifically incorporated into the neuron-specific nBAF complex<sup><xref ref-type="bibr" rid="R37">37</xref></sup> and are expressed at very low levels in both our iPSCs and neuroectoderm-like cells at Day-5 (<xref ref-type="fig" rid="F1">Fig. 1E</xref>).</p><p id="P10">This finding was particularly interesting given that DPF2 deletion has been linked to early neural ectoderm differentiation in embryonic stem cells (ESCs)<sup><xref ref-type="bibr" rid="R35">35</xref></sup>. DPF2 exists in two isoforms, resulting from alternative splicing of exon 7 and are spliced in a tissue-specific and developmental-stage-specific manner<sup><xref ref-type="bibr" rid="R38">38</xref></sup>. DPF2-L is not alternatively spliced and is expressed in ESCs, while DPF2-S is expressed in neurons. Interestingly, both isoforms are expressed in neural stem cells. Notably, of the two main SALL4 isoforms (SALL4A and SALL4B), SALL4B lacks the portion of exon 2 that contains ZFC3. This prompted us to explore whether the SALL4-DPF2 interaction could be isoform-specific. To address this, we reanalysed the interactions in AlphaFold3, incorporating SALL4B to the same BAF subunits as before. To ensure biological relevance, we first excluded two of the five models that did not exhibit interactions with the AT-rich DNA sequence, as SALL4 is expected to bind DNA for its function. Among the remaining three models, we observed that SALL4B interacted with DPF2, but unlike the SALL4A isoform, its interaction was not domain specific. Instead, the predicted interactions for SALL4B were characterized by annotated disordered regions and appeared to be largely driven by a non-specific, zinc-finger-to-zinc-finger association (<xref ref-type="fig" rid="F1">Fig. 1C</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>), with no particular domain-specific interactions identified. This pattern may be the result of the tendency of AlphaFold3 learning algorithm to associate similar domains, such as zinc fingers, based on their predicted functional specificity rather than spatial conformations. These findings suggest that, during neural ectoderm specification, SALL4 may associate with BAF in an isoform-dependent manner.</p><p id="P11">To accurately interpret our AlphaFold3 predictions, we examined two key confidence metrics: the Predicted Aligned Error (PAE), which assesses the reliability of the relative positioning of residues within the structure, and the Predicted Local Distance Difference Test (pLDDT), which provides a per-residue confidence score for the model. Our SALL4-DPF2 contact analysis revealed 394 atomic interactions (center-to-center distance ≤ 8Å) involving 139 residues (<xref ref-type="fig" rid="F1">Fig. 1B</xref>, right; <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>). Encouragingly, the pLDDT values were highest in known functional domains involved in the interaction, particularly ZF5, ZF6, and ZF7 in SALL4A, as well as the PHD1 and PHD2 domains in DPF2, reinforcing the reliability of these predicted structures. To refine our analysis, we focused on residues where at least half of their atomic interactions had a pLDDT &gt; 65 (70 ± 10%) and that were annotated as part of a functional domain, ensuring that only higher-confidence and potentially functional interactions were considered. As a result, ZF7 was excluded from further analysis (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>). In summary, our experiments and analyses confirm that SALL4 interacts with BAF during early stages of human CNCC specification, and predict that this interaction is mediated by the BAF subunit DPF2.</p></sec><sec id="S4"><title>Generation of a <italic>SALL4</italic>-haploinsufficient human iPSC line</title><p id="P12">Our experiments so far have revealed that SALL4 interacts with the BAF complex at early stages of CNCC specification, and specifically at the neuroectodermal stage (Day-5 of our iPSC-to-CNCC differentiation protocol). To investigate the scope of the SALL4-BAF interaction during this developmental process, we generated a <italic>SALL4</italic> haploinsufficient iPSC line (hereafter <italic>SALL4</italic>-het-KO; <xref ref-type="fig" rid="F2">Fig. 2A</xref>). We opted for a heterozygous KO of <italic>SALL4</italic> as this recapitulates the human <italic>SALL4</italic> syndromes, which are all caused by <italic>SALL4</italic> haploinsufficient genetic variants<sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R39">39</xref>,<xref ref-type="bibr" rid="R40">40</xref></sup>. The CRISPR-KO was generated by introducing a 11 bp deletion within the 3’-terminus of exon 1 of <italic>SALL4</italic>. This is a conserved region across both <italic>SALL4</italic> isoforms that lacks functionally significant domains.</p><p id="P13">SALL4 immunoblot confirmed that SALL4 protein expression was significantly reduced in the <italic>SALL4</italic>-het-KO iPSCs compared to the unedited wild-type line (<italic>SALL4</italic>-WT; <xref ref-type="fig" rid="F2">Fig. 2B</xref>). We noted that SALL4 expression in the <italic>SALL4</italic>-het-KO line was significantly less than the expected 50% of the wild-type, suggesting potential negative feedback mechanisms triggered by the reduced SALL4 levels, possibly due to the preferentially homodimeric nature of this protein.</p><p id="P14">Next, we investigated whether other SALL paralogs (<italic>SALL1, SALL2, SALL3</italic>) could compensate for the loss of SALL4. Thus, we investigated their expression at gene level (<xref ref-type="fig" rid="F2">Fig. 2C</xref>) and found that, while <italic>SALL2</italic> and <italic>SALL3</italic> were not differentially expressed at the RNA level, <italic>SALL1</italic> was instead significantly upregulated in the <italic>SALL4</italic>-het-KO cell line, at both RNA and protein level (<xref ref-type="fig" rid="F2">Figs. 2C and 2D</xref>), indicating a potential compensation in pluripotent cells.</p><p id="P15">Importantly, <italic>SALL4</italic>-het-KO iPSCs remain viable and exhibit hallmark iPSC morphology, including a high nucleus-to-cytoplasm ratio and growth in compact colonies with well-defined borders (<xref ref-type="fig" rid="F2">Fig. 2E</xref>). Furthermore, these cells show no significant difference in growth rate compared to their isogenic controls (<xref ref-type="fig" rid="F2">Fig. 2F</xref>).</p></sec><sec id="S5"><title>Decreased SALL4 expression does not affect the stem cell identity of the iPSCs</title><p id="P16">Given the debated role of SALL4 in maintaining pluripotency, we investigated whether <italic>SALL4</italic>-het-KO impacted iPSC stem cell identity. Thus, we examined the protein levels of the canonical pluripotency transcription factors NANOG and OCT4 and found that they remained unaltered in the <italic>SALL4</italic>-het-KO cells relative to the <italic>SALL4</italic>-WT control (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). Similarly, the levels of the pluripotency surface markers TRA-1-60-R and SSEA4 were also not significantly affected by decreased SALL4 expression (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). Moreover, we examined the transcriptome of the iPSCs using bulk RNA-seq and identified only 114 differentially expressed genes in <italic>SALL4</italic>-het-KO cells relative to the <italic>SALL4</italic>-WT control (FDR &lt; 0.05; <xref ref-type="fig" rid="F3">Fig. 3C</xref>). Gene Ontology analysis revealed that these genes were not enriched for pluripotency (<xref ref-type="fig" rid="F3">Fig. 3D and 3E</xref>). Finally, by performing tri-lineage differentiation we confirmed that decreased SALL4 expression levels did not impact the ability of the <italic>SALL4</italic>-het-KO cells to successfully differentiate into all three of the germ layers (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1A</xref>).</p><p id="P17">Together, these findings suggest that <italic>SALL4</italic> haploinsufficiency does not affect the stem cell identity and self-renewal of human iPSCs, possibly as a result of SALL1-mediated compensation.</p></sec><sec id="S6"><title>SALL4 relocates to CNCC developmental enhancers upon CNCC induction cues</title><p id="P18">After establishing that <italic>SALL4</italic>-het-KO did not affect iPSC stem cell identity, we differentiated the iPSCs into CNCCs using the same aforementioned protocol<sup><xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R31">31</xref></sup> (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). Since the SALL4-BAF interaction was detected at Day-5 of this protocol<sup><xref ref-type="bibr" rid="R27">27</xref></sup> (neuroectodermal stage), we profiled SALL4 binding in <italic>SALL4</italic>-WT cells by performing CUT&amp;RUN at the iPSC stage and at Day-5 of differentiation. We performed two SALL4 CUT&amp;RUN replicates per timepoint, and only retained replicated peaks in each timepoint (FDR &lt; 0.05). With this approach, we identified comparable amounts of SALL4-bound genomic sites at Day-0 and Day-5 (29,088 and 32,707, replicated peaks, respectively, FDR &lt; 0.05). Further analysis of these sites indicated that approximately 20% of the Day-0 SALL4 peaks were unique to the iPSC stage and not detected at Day-5 (hereafter SALL4 Day-0 specific peaks; n=6,114; <xref ref-type="fig" rid="F4">Fig. 4B</xref>, left). On the other hand, ~50% of the peaks detected at Day-5 were exclusive of this developmental stage and were not detected at Day-0 (hereafter SALL4 Day-5-specific peaks, n= 17,137; <xref ref-type="fig" rid="F4">Fig. 4B</xref>, right). Finally, a subset of ~15,000 sites remained bound by SALL4 throughout exit from pluripotency to neural ectoderm cell fate commitment (i.e. peaks conserved and replicated between Day-0 and Day-5). Together, this data indicate that, upon differentiation cues, there is a major shift in SALL4 binding, resulting in the relocation of this transcription factor at ~17,000 previously unbound regions.</p><p id="P19">To understand the scope of SALL4’s relocation, we analysed the positional distribution of the SALL4 peaks by associating each peak with the nearest transcription start site (TSS). Consistent with SALL4’s role as an enhancer-binding transcription factor, 86% of SALL4-bound regions at Day-0 were located &gt;1Kb from the nearest TSS (n= 3,729), indicating they could be putative enhancers. This proportion increased even further to 97% (n= 6,860) at Day-5, further emphasizing the preferential binding of SALL4 at enhancer regions (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). To investigate the scope of the newly acquired SALL4 Day-5 peaks, we first looked at the nearest genes. GO terms enriched in the “Day-5 specific” genes included pathways associated with neural crest development, such as neural tube development, face development, cardiac chamber development, and cell-cell adhesion mediated by cadherin (<xref ref-type="fig" rid="F4">Fig. 4D</xref>; FDR &lt; 0.05, clustered using affinity propagation redundancy removal parameter).</p><p id="P20">To further characterise the SALL4 bound enhancers and promoters at Day-0 and Day-5, we performed sequence-based computational motif analysis. At Day-0, motifs associated with core pluripotency transcription factors such as OCT4, NANOG, and SOX2 did not rank among the top 20 enriched sequences, further supporting the notion that SALL4 may not be essential for maintaining pluripotency in human cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2A</xref>). Moreover, Day-0 specific</p><p id="P21">SALL4 peaks were enriched for the enhancer box (E-box) motif (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2A</xref>). The E-box is usually bound by homo- or heterodimers of transcription factors containing a basic Helix-Loop-Helix (bHLH) or a Zn-finger domain to regulate the expression of genes associated to cell lineage commitment, especially in the context of skeletal muscle, cardiovascular and neuronal tissue<sup><xref ref-type="bibr" rid="R41">41</xref></sup>. On the other hand, in addition to general enhancer activator factors (AP-1, TEAD), the Day-5 specific SALL4 peaks were enriched for many CNCC signature factors, including SOX9, TFAP2A, TWIST1/2, SNAI1, NR2F1/2, TCF4/12 and several others (<xref ref-type="fig" rid="F4">Fig. 4E</xref>). Moreover, neuroectodermal transcription factors, such as ZIC2/3 were also enriched. In summary, this analysis suggests that, as early as the neuroectodermal stage, SALL4 relocates to enhancers of genes associated with craniofacial development.</p></sec><sec id="S7"><title>Chromatin accessibility at the CNCC enhancers is SALL4 dependent</title><p id="P22">Given that we demonstrated that SALL4 interacts with BAF at early stages of CNCC specification, we reasoned that SALL4 binding at the CNCC developmental enhancers could be necessary for their chromatin activation. Thus, we profiled chromatin accessibility by performing ATAC-seq at Day-0 and Day-5 in both <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO conditions (two replicates per timepoint per condition, only peaks present in both replicates were considered; FDR &lt; 0.05). The number of ATAC-seq replicated peaks identified in <italic>SALL4</italic>-WT condition was comparable between Day-0 (61,660 peaks; FDR &lt; 0.05) and Day-5 (58,375 peaks; FDR &lt; 0.05). Next, we specifically investigated the chromatin state of the 17,137 genomic sites that gain SALL4 binding at Day-5 and found that SALL4 binding at these sites correlates with a marked increase in chromatin accessibility compared to Day-0 (<xref ref-type="fig" rid="F4">Fig. 4F</xref>). Strikingly, the accessibility at these regions was significantly attenuated in <italic>SALL4</italic>-het-KO relative to <italic>SALL4</italic>-WT (<xref ref-type="fig" rid="F4">Fig. 4G</xref>). Overall, these findings suggest that, in response to differentiation signals, SALL4 relocates to CNCC developmental enhancers, which subsequently become activated through chromatin opening, which is SALL4 dependent.</p></sec><sec id="S8"><title>SALL4 recruits the BAF complex at CNCC developmental enhancers to increase chromatin accessibility</title><p id="P23">Since SALL4 binding at the CNCC enhancers is necessary for chromatin opening, we sought to determine whether the SALL4-bound developmental enhancers were also occupied by BAF, and if BAF binding at these sites could be SALL4 dependent. We performed ChIP-seq for BRG1 (SMARCA4), the only catalytic subunit of BAF active at this time point, in <italic>SALL4</italic>-WT cells at Day-5 of the iPSC-to-CNCC differentiation protocol. This experiment revealed that BRG1 consistently binds the same genomic sites as SALL4, supporting the idea that these factors interact and co-occupy regulatory elements during early differentiation (<xref ref-type="fig" rid="F5">Fig. 5A</xref>).</p><p id="P24">To assess whether BRG1 binding depends on SALL4, we performed ChIP-seq for BRG1 in both <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO cells at Day-5. In <italic>SALL4</italic>-WT cells, we detected 32,833 replicated BRG1 peaks (FDR &lt; 0.05), as opposed to only 14,116 peaks in <italic>SALL4</italic>-het-KO cells. This suggested that SALL4 loss leads to a widespread loss of BAF from chromatin. We thus focused on the BRG1 peaks that were lost in <italic>SALL4</italic>-het-KO cells and found that these sites were largely not bound by SALL4 at Day-0, but they gained SALL4 binding at Day-5 (<xref ref-type="fig" rid="F5">Figs. 5B and 5C</xref>). As expected, loss of SALL4 and BRG1 from these sites led to marked decrease of chromatin accessibility (<xref ref-type="fig" rid="F5">Fig. 5D</xref>). Overall, these experiments support that SALL4 is required to recruit the BAF complex at CNCC enhancers. Consistent with this, genes near BRG1 peaks lost in the <italic>SALL4</italic>-het-KO cells are involved in embryonic organ development, epithelial differentiation, and cell migration processes (<xref ref-type="fig" rid="F5">Fig. 5E</xref>).</p><p id="P25">While a large portion of BRG1 peaks was lost in the absence of SALL4, we also identified a subset of novel BRG1 peaks that were absent in <italic>SALL4</italic>-WT cells but gained in the <italic>SALL4</italic>-het-KO cells. These BRG1 peaks gained in the <italic>SALL4</italic>-het-KO cells were associated with genes linked to neurogenesis and nervous system development (<xref ref-type="fig" rid="F5">Fig. 5F</xref>). These findings indicate that, in the absence of SALL4, BRG1 is relocated from CNCC enhancers to neurodevelopmental enhancers, shifting chromatin remodeling activity away from CNCC specification.</p><p id="P26">Together, these results suggest that SALL4 is a key regulator of BAF complex recruitment to CNCC-specific enhancers, ensuring their accessibility during differentiation. In the absence of SALL4, BRG1 fails to localize to these sites and is instead partially redirected to neurodevelopmental enhancers, leading to a misallocation of chromatin remodeling activity, potentially leading to a shift towards neural differentiation at the expense of CNCC induction and specification.</p></sec><sec id="S9"><title><italic>SALL4</italic>-het-KO cells are not able to exit the neural ectoderm stage and to induce the cranial neural crest fate</title><p id="P27">Our data thus far indicate that SALL4 relocates to CNCC enhancers as early as the neuroectodermal stage, recruiting BAF to these regulatory elements for chromatin activation. Next, we investigated the functional consequences of SALL4 loss by generating CNCCs using <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO cells. As expected, the <italic>SALL4</italic>-WT CNCCs expressed the signature CNCC markers at both the RNA (<xref ref-type="fig" rid="F6">Fig. 6A</xref>) and protein (<xref ref-type="fig" rid="F6">Fig. 6B</xref>) level, while <italic>SALL4</italic>-het-KO showed a significant downregulation of these genes (<xref ref-type="fig" rid="F6">Fig. 6A</xref>). This was further supported by RNA-seq conducted at Day-14, which identified 1,106 differentially expressed genes in <italic>SALL4</italic>-het-KO CNCCs relative to <italic>SALL4</italic>-WT (FDR &lt; 0.05; <xref ref-type="fig" rid="F6">Fig. 6C</xref>). This is in sharp contrast with the small number of genes differentially expressed at the iPSC stage (n= 114; <xref ref-type="fig" rid="F3">Fig. 3C</xref>) and at Day-5 (n= 170; <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2B</xref>).</p><p id="P28">Of the 1,106 genes differentially expressed at Day-14, ~60% (n= 659) were downregulated while the remaining were upregulated (<xref ref-type="fig" rid="F6">Fig. 6C</xref>). Remarkably, canonical CNCC markers such as TFAP2A, NR2F1, and SOX9 were significantly downregulated in <italic>SALL4</italic>-het-KO cells. Additionally, genes associated with neural plate border, early neural crest induction and epithelial-to-mesenchymal transition (EMT) were also downregulated (<italic>MSX1, GBX2, SNAI2, SOX5, ZEB1/2</italic>; <xref ref-type="fig" rid="F6">Fig. 6C</xref>). In line with these findings, gene ontology analysis revealed that pathways associated with face development, autonomic nervous system, gastrulation, and regulation of morphogenesis were all downregulated (<xref ref-type="fig" rid="F6">Fig. 6D</xref>). The 447 upregulated genes were instead involved in regulatory pathways, especially vesicle-mediated transport of inorganic substances. As aforementioned, genes associated with EMT were also dysregulated. The process of EMT requires a switch in cadherin expression where E-cadherin (<italic>CDH1</italic>) must be downregulated, while N-cadherin (<italic>CDH2</italic>) must be upregulated. Remarkably, our RNA-seq data revealed that this cadherin switch did not occur in the differentiating <italic>SALL4</italic>-het-KO iPSCs, suggesting that the cells remained in an epithelial state. This was further corroborated by the upregulation of several epithelial genes in the differentiating <italic>SALL4</italic>-het-KO cells, including <italic>EpCAM, OTX2, CDH1</italic>, and <italic>OVOL2</italic> (<xref ref-type="fig" rid="F6">Fig. 6E</xref>). The latter is involved in maintaining epithelial lineages by repressing the expression of the EMT gene <italic>ZEB1</italic>, which was downregulated in the <italic>SALL4</italic>-het-KO condition<sup><xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R43">43</xref></sup>. In summary, our data indicate that CNCC specification failed in <italic>SALL4</italic>-het-KO conditions, as reflected by the large number of differentially expressed genes. On the other hand, the transcriptome of the iPSCs and of the neuroectodermal cells (i.e. Day-5) were only modestly affected by SALL4 loss, suggesting that SALL4 may not be essential for neuroectoderm formation, while it is essential for CNCC induction and specification.</p><p id="P29">To investigate this further, we systematically examined the expression of a panel of stage-specific marker genes at Day-0, Day-5 and Day-14 (<xref ref-type="fig" rid="F6">Fig. 6F</xref>) including core pluripotency genes (<italic>POU5F1</italic> and <italic>NANOG</italic>), neural plate border specifiers (<italic>ZIC1, GBX2, MSX1/2, PAX3/7, DLX5/6, GATA2/3</italic>), CNCC specification markers (<italic>SNAI1/2, SOX9, TFAP2A</italic>), and post-migratory CNCC markers (<italic>SOX5, SOX6, SOX10</italic>). In <italic>SALL4</italic>-WT cells, pluripotency markers exhibited a progressive and expected downregulation as differentiation advanced from Day-0 to Day-14. In <italic>SALL4</italic>-het-KO cells, a similar decline in pluripotency markers was observed between Day-0 and Day-5, but instead of continuing to decrease, these markers remained similarly expressed through Day-14</p><p id="P30">(<xref ref-type="fig" rid="F6">Fig. 6F</xref>). Despite this, the two conditions showed similar trends, confirming that decreased levels of SALL4 dId not significantly impact pluripotency markers expression during exit from pluripotency. Similarly, no significant difference was observed in the expression of neural plate border specifiers (<xref ref-type="fig" rid="F6">Fig. 6G</xref>), suggesting that SALL4 is not required for neuroectoderm specification. Conversely, CNCC specification markers and post-migratory CNCC markers all increased in expression after Day-5 in <italic>SALL4</italic>-WT cells, while the SALL4-depleted cells failed to maintain a comparable increase in expression (<xref ref-type="fig" rid="F6">Fig. 6H and 6I</xref>).</p><p id="P31">In summary, <italic>SALL4</italic>-het-KO cells are competent to generate neuroectoderm-like cells (Day-5) but fail to induce the neural crest lineage (Day-14).</p></sec></sec><sec id="S10" sec-type="discussion"><title>Discussion</title><p id="P32">During embryonic development, SALL4 plays a critical role in forming major anatomical structures, including the heart, limbs, cerebral midline, and pituitary gland<sup><xref ref-type="bibr" rid="R44">44</xref></sup>. Correspondingly, mutations in the haploinsufficient gene <italic>SALL4</italic> are associated with congenital syndromes characterized by malformations in these structures. These syndromes also frequently include distinct craniofacial anomalies, such as epicanthal folds, hypertelorism, a depressed nasal bridge, and hemifacial microsomia<sup><xref ref-type="bibr" rid="R45">45</xref>–<xref ref-type="bibr" rid="R47">47</xref></sup>, all of which are hallmark features of disrupted cranial neural crest cell development.</p><p id="P33">Notably, at the murine embryonic stage E9.5, Sall4 expression persists within the frontonasal prominence, which is the most anterior embryonic region<sup><xref ref-type="bibr" rid="R18">18</xref></sup>, implying a potential role for SALL4 in craniofacial development. Given the limited existing knowledge about SALL4 function in this context, we utilized a heterozygous <italic>SALL4</italic> knockout human induced pluripotent stem cell (iPSC) line to investigate its role during cranial neural crest cell (CNCC) specification. Although SALL4 expression begins as early as the 2-cell embryonic stage, its role in maintaining pluripotency remains debated. Some studies indicate that SALL4 cooperates closely with key pluripotency factors such as OCT4 and NANOG to sustain stem cell identity<sup><xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref></sup>. Others, however, report that SALL4 has only limited involvement within pluripotency regulatory networks<sup><xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup>. Our findings align with the latter hypothesis, demonstrating that decreased expression of SALL4 does not compromise iPSC identity, possibly due to compensatory mechanisms involving its paralogue, SALL1.</p><p id="P34">Using CUT&amp;RUN, we observed that at early stages of CNCC induction, SALL4 relocates to enhancers of genes involved in CNCC formation, and that SALL4 binding at these regulatory elements is required for their activation. In humans, SALL4 exists in two major isoforms generated by alternative splicing: SALL4A (1,053 amino acids), which retains all eight zinc-finger motifs, and SALL4B (617 amino acids), which contains a partially spliced exon 2. Rao et al.<sup><xref ref-type="bibr" rid="R12">12</xref></sup> proposed distinct functional roles for these isoforms in murine ESCs, demonstrating that SALL4A homodimers localize predominantly to enhancers of developmental genes, whereas pluripotency-associated enhancers are occupied either by heterodimers comprising both isoforms or by SALL4B alone. In mouse ESCs, approximately 10% of the total Sall4 protein, and primarily the Sall4A isoform, is incorporated into the NuRD complex <sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>. Here, we identify and characterize a novel interaction between SALL4 and the BAF complex, predicted to be mediated specifically through the SALL4A isoform and the BAF subunit DPF2. Furthermore, we show that upon receiving CNCC induction cues, SALL4 and BAF co-localize to enhancers of genes involved in CNCC specification to prime and activate them, with BAF recruitment being SALL4-dependent.</p><p id="P35">Interestingly, DPF2 and SALL4 exhibit notable functional parallels. Similar to SALL4, DPF2 occupancy undergoes significant repositioning during the transition from pluripotency toward early neural commitment in mouse embryoid bodies <sup><xref ref-type="bibr" rid="R48">48</xref></sup>. Although the role of DPF2 in CNCCs has not been directly investigated, its early recruitment to neuronal enhancers suggests a potential involvement in neuroectodermal differentiation and the subsequent lineage commitment of neuroectoderm-derived cells, including CNCCs. Moreover, genomic sequences bound by DPF2 in mouse neuroectodermal cells are AT-rich, resembling the preferred binding motif of SALL4<sup><xref ref-type="bibr" rid="R38">38</xref>,<xref ref-type="bibr" rid="R49">49</xref>,<xref ref-type="bibr" rid="R50">50</xref></sup>.</p><p id="P36">Our study demonstrated that while cranial neural crest cell induction and specification fail in the absence of SALL4, early neuroectodermal commitment remains unaffected (<xref ref-type="fig" rid="F7">Fig. 7</xref>). This finding is further supported by clinical observations. In fact, phenotypes arising from SALL4 haploinsufficiency affect many neural crest derivatives, including craniofacial structures and peripheral neurons. In contrast, phenotypes implicating defects in neural ectoderm or neurogenesis are exceptionally rare<sup><xref ref-type="bibr" rid="R51">51</xref>,<xref ref-type="bibr" rid="R52">52</xref></sup> and usually associated with dysregulation of potassium channels<sup><xref ref-type="bibr" rid="R44">44</xref></sup>. In the rare cases of intellectual disability reported, such phenotypes were attributed to broader deletions on chromosome 20q13.13-q13.2 rather than <italic>SALL4</italic> loss alone<sup><xref ref-type="bibr" rid="R51">51</xref></sup>.</p><p id="P37">SALL4 was recently identified as a direct target of thalidomide<sup><xref ref-type="bibr" rid="R53">53</xref></sup>, a drug widely prescribed to pregnant women in the late 1950s to alleviate morning sickness. The subsequent alarming rise in births of children with congenital anomalies, including limb malformations (phocomelia), facial abnormalities such as inner ear defects, ocular motility issues, and facial nerve palsy, as well as kidney and heart defects, led to the identification of thalidomide as the causative agent. However, the molecular mechanism by which thalidomide induced these developmental defects remained elusive until nearly six decades after the drug’s withdrawal from the market. Building on earlier findings that thalidomide and its derivatives bind to cereblon (CRBN), Matyskiela et al.</p><p id="P38">demonstrated that SALL4 is recruited to the CRL4–CRBN E3 ubiquitin ligase complex following thalidomide-induced ubiquitination, resulting in its proteasomal degradation<sup><xref ref-type="bibr" rid="R54">54</xref></sup>. More recently, research demonstrated that only the SALL4A isoform, but not SALL4B, is susceptible to degradation by immunomodulatory imide drugs such as thalidomide and its derivative pomalidomide<sup><xref ref-type="bibr" rid="R55">55</xref></sup>. In this context, our findings might contribute to shed light on the birth malformations caused by thalidomide in the 1960s, potentially revealing some of the underlying mechanisms.</p></sec><sec id="S11"><title>Resource Availability</title><sec id="S12"><title>Lead contact</title><p id="P39">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Marco Trizzino (<email>m.trizzino@imperial.ac.uk</email>).</p></sec></sec><sec id="S13" sec-type="methods" specific-use="web-only"><title>Methods</title><sec id="S14"><title>Key Resources Table</title><table-wrap id="T1" orientation="portrait" position="anchor"><table frame="box" rules="groups"><thead><tr><th valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid #000000">REAGENT OR RESOURCE</th><th valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid #000000">SOURCE</th><th valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">IDENTIFIER</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><bold>Antibodies</bold></td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">Brg1 (D1Q7F)</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">Cell Signaling Technology</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_2728743</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">CD99 Antibody, anti-human, Vio®<break/>Bright B515, REAfinity™</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Miltenyi Biotec</td><td valign="top" align="left" style="border:solid 1px #000000">AB_2784331</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">GAPDH (D16H11) XP Rabbit mAb</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Cell Signaling Technology</td><td valign="top" align="left" style="border:solid 1px #000000">AB_10622025</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Human Nanog Antibody</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">R&amp;D Systems</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_355097</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Human/Mouse Oct-3/4 Antibody</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">R&amp;D Systems</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_354975</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">SALL1 Polyclonal Antibody</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Thermo Fisher Scientific</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_2900498</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Sall4 (EE-30)</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Santa Cruz Biotechnology</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_1129262</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Sall4 (D16H12) Rabbit mAb</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Cell Signaling Technology</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_10949321</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">APC anti-human SSEA-4</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Biolegend</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_2616818</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PE anti-human TRA-1-60-R</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Biolegend</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_1279447</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Rabbit IgG, monoclonal<break/>[EPR25A] Antibody</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Abcam</td><td valign="top" align="left" style="border:solid 1px #000000">AB_2687931</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">AP2 alpha Monoclonal Antibody (3B5)</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermo Fisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">AB_2199412</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">CD326 (EpCAM) Monoclonal<break/>Antibody (1B7), eBioscience</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermo Fisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">AB_795876</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Anti-SOX9 antibody</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Abcam</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_2715497</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Vimentin Polyclonal Antibody</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Thermo Fisher Scientific</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_2216267</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">ARID1B antibody</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Abcam</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">AB_2243092</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">IRDye 800CW Goat anti-Rabbit IgG</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">LI-COR Biosciences</td><td valign="top" align="left" style="border:solid 1px #000000">AB_621843</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">Goat polyclonal Secondary Antibody to Mouse (IRDye® 800CW)</td><td valign="top" align="left" style="border:solid 1px #000000">LI-COR Biosciences</td><td valign="top" align="left" style="border:solid 1px #000000">AB_10859231</td></tr><tr><td valign="top" align="left" style="border-left: 1px solid">Donkey anti-Rabbit IgG (H+L)<break/>Highly Cross-Adsorbed<break/>Secondary Antibody, Alexa<break/>Fluor™ Plus 488</td><td valign="top" align="left" style="border-left:solid 1px #000000">Thermo Fisher Scientific</td><td valign="top" align="left" style="border-left:solid 1px #000000;border-right:solid 1px #000000">AB_2762833</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ Plus 647</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermo Fisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">AB_2762830</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Goat anti-Chicken IgY (H+L) Secondary Antibody, Alexa Fluor™ 488</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermo Fisher Scientific</td><td valign="top" align="left" style="border:solid 1px #000000">AB_2534096</td></tr><tr><td valign="top" align="left" colspan="3" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><bold>Critical commercial assays</bold></td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">ATAC-Seq Kit</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">Active Motif</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">53150</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Human Pluripotent Stem Cell<break/>Functional Identification Kit</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">R&amp;D Systems</td><td valign="top" align="left" style="border:solid 1px #000000">SC027B</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Monarch® Total RNA Miniprep Kit</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">New England Biolabs</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">T2010S</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Maxima First Strand cDNA<break/>Synthesis Kit for RT-qPCR</td><td valign="top" align="left" style="border-top:solid 1px #000000;border-left:solid 1px #000000">Thermo Fisher</td><td valign="top" align="left" style="border:solid 1px #000000">K1641</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">NEBNext® Ultra™ II Directional<break/>RNA Library Prep Kit for<break/>Illumina®</td><td valign="top" align="left" style="border-top:solid 2px #000000;border-left:solid 1px #000000">New England Biolabs</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">E7760L</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">CUT&amp;RUN Assay Kit</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">Cell Signaling Technology</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">86652</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">NEBNext® Ultra™ II DNA Library<break/>Prep Kit for Illumina®</td><td valign="top" align="left" style="border-top:solid 2px #000000;border-left:solid 1px #000000">Cell Signaling Technology</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">E7645L</td></tr><tr><td valign="top" align="left" colspan="3" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><bold>Experimental models: Cell lines</bold></td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">PENN123i-SV20</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">iPSC Core of the University of Pennsylvania</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">CVCL_EL23</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">PENN123i-SV20 <italic>SALL4</italic>-het-KO<break/>iPSC</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">Synthego</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"/></tr><tr><td valign="top" align="left" colspan="3" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><bold>Oligonucleotides</bold></td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">18S</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">5’-ATACATGCCGACGGGCGCTG-3’</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">5’-AGGGCTGACCGGGTTGGTT-3’</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">TFAP2A</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">5’-GCCTCTCGCTCCTCAGCTCC-3’</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">5’-CGTTGGCAGCTTTACGTCTCCC-3’</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">NR2F1</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid">5’-ATCGTGCTGTTCACGTCAGA-3’</td><td valign="top" align="left" style="border: 1px solid">5’-GCTCCTCACGTACTCCTCCA-3’</td></tr><tr><td valign="top" align="left" style="border-left: 1px solid">SOX9</td><td valign="top" align="left" style="border-left: 1px solid">5’-GTACCCGCACTTGCACAAC-3’</td><td valign="top" align="left" style="border-left: 1px solid #000000;border-right: 1px solid">5’-TCTCFCTCTCGTTCAGAAGTC-3’</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">SALL1</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">5’-CCCAGTGTGTGTCCTGTAGT-3’</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">5’-CCACCTTCACCAACCCTTTG-3’</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">SALL2</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">5’-TAGGTGTTGTGTAGGCTGGG-3’</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">5’-CTCACTTCCATTCCCACCCT-3’</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">SALL3</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">5’-GCGCTGCGTAAAGATGAGAA-3’</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">5’-GGCTACCCTGTCTGTTGAGT-3’</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">SALL4</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">5’-GGCATCCAGAGACAGACCTT-3’</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">5’-GGTCCTCGAGCAGATCTTGT-3’</td></tr><tr><td valign="top" align="left" colspan="3" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"><bold>Software and algorithms</bold></td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">AlphaFold3</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid"><ext-link ext-link-type="uri" xlink:href="https://alphafoldserver.com/">https://alphafoldserver.com/</ext-link></td><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">SCR_025454</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">TrimGalore!</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</ext-link></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">SCR_011847</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">FlowJo Software version 10.9</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">SCR_008520</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">BEDTools</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">SCR_006646</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid">Deeptools</td><td valign="top" align="left" style="border-top: 2px solid #000000;border-left: 1px solid"/><td valign="top" align="left" style="border-top: 2px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">SCR_016366</td></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">R Studio version 4.4.3</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"/><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid"/></tr><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid">GraphPad Prism 10.2.3</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-left: 1px solid"><ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/faq/viewfaq.cfm?faq=1362">http://www.graphpad.com/faq/viewfaq.cfm?faq=1362</ext-link></td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid">SCR_002798</td></tr><tr><td valign="top" align="left" style="border-top: 2px solid #000000;border-bottom: 2px solid #000000;border-left: 1px solid">DESeq2</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid"/><td valign="top" align="left" style="border: 1px solid">SCR_015687</td></tr></tbody></table></table-wrap></sec></sec><sec id="S15"><title>Method Details</title><sec id="S16"><title>AlphaFold3 structure prediction</title><p id="P40">FASTA files for each BAF subunits and SALL4 isoforms were collected from the “Sequence &amp; Isoforms” section of Uniprot (<ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org">www.uniprot.org</ext-link>). The AT-rich DNA sequences was collected from an empirically reported crystal structure of SALL4 zinc finger cluster 4 bound to DNA on RCSB PDB (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">www.rcsb.org</ext-link>, 8A4I – DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb8A4I/pdb">https://doi.org/10.2210/pdb8A4I/pdb</ext-link>). FASTA sequences are listed in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>. AlphaFold outputs were downloaded and .cif files were analysed using UCSF ChimeraX-1.9 (<ext-link ext-link-type="uri" xlink:href="https://www.rbvi.ucsf.edu/chimerax">https://www.rbvi.ucsf.edu/chimerax</ext-link>). Contacts were found using default parameters and center-center distance ≤ 8 Å.</p></sec><sec id="S17"><title>Human iPSC culture</title><p id="P41">Wild-type iPSC lines were obtained from the iPSC Core of the University of Pennsylvania (Control line-1: SV20 line, male, age 43). iPSC lines were cultured in feeder-free, serum-free mTeSR Plus medium (STEMCELL Technologies) with 1% Penicillin-Streptomycin (5,000 U/mL; Gibco #15140122) on tissue culture plates coated overnight with Geltrex™ LDEV-Free hESC-qualified Reduced Growth Factor Basement Membrane Matrix (Fisher-Scientific). Cells were passaged ~1:8 at 60-80% confluency using 0.5mM EDTA to create 50-200 cell clusters.</p></sec><sec id="S18"><title>CRISPR/Cas9-mediated SALL4 knock-out</title><p id="P42">The heterozygous <italic>SALL4</italic> knock-out in the human SV20 iPSC line was generated via CRISPR/Cas9 gene-editing by the biotech company Synthego. Specifically, Cas9 targeted the first exon of the <italic>SALL4</italic> gene in the established SV20 iPSC line producing an 11-base deletion (c.230delGGGCCGCATCT) which generated a premature stop codon.</p></sec><sec id="S19"><title>Trilineage differentiation</title><p id="P43">iPSCs were differentiated into the three germ layers (endoderm, ectoderm and mesoderm) using the Human Pluripotent Stem Cell Functional Identification Kit (R&amp;D Systems, SC027B). The expression of relevant markers was then assessed using immunofluorescence with 10 ug/ml of antibodies provided in the kit (Goat anti-human SOX17, Goat anti-human OTX2 and, Goat anti-human Brachyury).</p></sec><sec id="S20"><title>iPSC-to-CNCC differentiation</title><p id="P44">All iPSC lines were differentiated into CNCCs as previously described (Prescott et al., 2015). Briefly, iPSCs at 60% confluence were treated with CNCC differentiation media (1:1 Neurobasal medium/D-MEM F-12 medium (Invitrogen), 0.5× B-27 supplement with Vitamin A (50× stock, Gibco, #17504044), 0.5× N-2 supplement (100× stock, Gibco; #17502001), 20 ng/ml human FGF (Gibco), 20 ng/ml recombinant EGF (Sigma-Aldrich), 5 μg/ml bovine insulin (Sigma-Aldrich) and 1× Glutamax-I supplement (100× stock, Invitrogen). Medium (2 ml) was changed every other day. Around day 7-9 of differentiations, cells were transitioned to CNCC early maintenance media (1:1 Neurobasal medium/D-MEM F-12 medium (Invitrogen), 0.5× B-27 supplement with Vitamin A (50× stock, Invitrogen), 0.5× N-2 supplement (100× stock, Invitrogen), 20 ng/ml bFGF (Biolegend), 20 ng/ml EGF (Sigma-Aldrich), 1 mg/ml bovine serum albumin, serum replacement grade (Gemini Bio-Products # 700-104 P) and 1× Glutamax-I supplement (100× stock, Invitrogen). Differentiating cells were passaged ~1:6 with 0.5mM EDTA or Accutase Cell Detachment Solution (Stemcell Technologies; #07920), plated in a fresh, Geltrex-coated 6-well plates. After passaging, cells were treated with 0.05% ROCK-inhibitor (Y27632; Stemcell Technologies) for 24 hours.</p></sec><sec id="S21"><title>Real-time quantitative polymerase chain reaction (RT-qPCR)</title><p id="P45">Cells were harvested as single cells, and the total RNA was extracted using Monarch® Total RNA Miniprep Kit (New England Biolabs) following manufacturer’s instructions. 600ng of total RNA was used to synthesize cDNA using Maxima First Strand cDNA Synthesis Kit for RT-qPCR (K1641, Thermo Fisher). For each RT-qPCR reaction, 15 ng of cDNA was used with 0.1 μM of each primer, 10 μL of PowerUp™ SYBR™ Green Master Mix (Applied Biosystems) in a final volume of 20 μl. Samples were analyzed with CFX Connect Real-Time PCR Detection System (Bio-Rad) using the following thermal cycling parameters: 3 min at 95 °C, followed by 40 cycles of 10 s at 95 °C, 20 s at 63 °C followed by 30 s at 72 °C. Each sample was run in triplicate. 18 S rRNA was used as normalizer.</p></sec><sec id="S22"><title>Nuclear Fractionation and Co-immunoprecipitation</title><p id="P46">Cells were washed twice with ice-cold PBS, scraped, and collected by centrifugation at 10,000 × g for 1 minute. Pellets were resuspended in 500 μL of Buffer A (10mM HEPES, 1.5mM Mg2Cl,10mM KCl, 1mM EDTA, 0.5mM DTT) and cytoplasmic fractions were obtained by incubating the cells on ice for 15 minutes, adding of 0.05% NP-40, followed by centrifugation at 17,000 × g for 10 minutes at 4 °C. The resulting pellet was gently washed with Buffer A and resuspended in Buffer C (10mM HEPES, 1.5mM Mg2Cl, 300mM NaCl, 0.2mM EDTA, 0.5mM DTT, 26% glycerol). Samples were incubated at 4 °C with shaking at 3,400 rpm for 1 hour, with vortexing every 10 minutes. Nuclear fractions were collected by centrifugation at 17,000 × g for 10 minutes at 4 °C.</p><p id="P47">For co-immunoprecipitation (co-IP), 25 μL of Dynabeads™ Protein A (ThermoFisher, Cat# 10002D) were washed twice with PBS containing 0.1% Tween-20 (PBS-T), resuspended in 1 mL of PBS-T, and incubated with 2 μg of the appropriate antibody for 1 hour at 4 °C with rotation. Bead-antibody complexes were washed twice with PBS-T, resuspended in 125 μL PBS-T, and incubated with 100 μg of nuclear extract for 3 hours at 4 °C with rotation. Beads were then washed five times with Buffer C and eluted in 25 μL of Buffer C supplemented with 4.1 μL of 6× reducing Laemmli SDS sample buffer (ThermoFisher Scientific). Eluates and 5% input controls (nuclear extract diluted 1:10 in PBS and mixed with 1:6 volume of 6× Laemmli buffer) were boiled for 5 minutes prior to SDS-PAGE. For Western blotting, 20 μL of each sample were loaded as described below.</p></sec><sec id="S23"><title>Western Blot</title><p id="P48">For each condition, cells were harvested and lysed with cold radioimmunoprecipitation assay buffer (Pierce™ RIPA buffer, Thermo Fisher) with Pierce™ Protease Inhibitor Mini Tablets, EDTA-free (Thermo Fisher). After centrifugation at 4°C at 16,000x g for 10 minutes, the total extracted protein was quantified using Pierce™ BCA Protein Assay Kit, following manufacturer’s indications. Thirty micrograms of total protein were loaded in Novex WedgeWell 4–20% Tris-Glycine Gel (Invitrogen) and separated through gel electrophoresis (SDS–PAGE) Tris-Glycine-SDS buffer (Invitrogen). The proteins were then transferred to nitrocellulose membrane (Thermo Fisher Scientific) and incubated for one hour in Intercept® (PBS) Blocking Buffer (Licor). After blocking, membranes were incubated overnight at 4°C (while rocking) in suitable antibody diluted in blocking buffer and 0.2% Tween-20, at recommended concentrations. Membranes were washed in 0.1% PBS-T before and after being incubated for one hour in the appropriate secondary antibody (1:15,000 dilution). The antibodies were then visualized using Odyssey XF Imaging System (Licor) or ChemiDocTM MP Imaging System and imaged with Image Studio Software (Licor) or Fiji<sup><xref ref-type="bibr" rid="R58">58</xref></sup>.</p></sec><sec id="S24"><title>Flow Cytometry analysis of surface markers</title><p id="P49">To obtain a single-cell suspension for flow cytometry analysis, cells were treated with Accutase for 5 min at 37°C. Cells were then washed with cold phosphate-buffered saline (PBS)-2% fetal bovine serum (FBS) and live cells were counted. 1 × 106 cells/condition were resuspended in 100 μL PBS-2% FBS and stained. For pluripotency evaluation, 4 μl of the respective antibodies were used. For analysis of differentiation, 2 μl of the respective antibodies were used. Cells were incubated for 15 min on ice and protected from light, before transferring them into FACS tubes containing an additional 300 μL PBS-2% FBS. Flow cytometry data were acquired using NovoCyte Penteon Flow Cytometer Systems 5 Lasers and analyzed with FlowJo Software version 10.9.</p></sec><sec id="S25"><title>Immunofluorescence</title><p id="P50">Cells were passaged onto Geltrex-coated coverslips and fixed at required confluence or time-point. In detail, cells were incubated in 4% PFA at 37°C for 15 minutes, followed by three 2-minute washes in 1× PBS. For permeabilization, cells were treated with 0.1% (v/v) Triton X-100 (T8787, Sigma-Aldrich) at room temperature for 10 minutes before three 2-minute washes in 1× PBS + 0.1% (v/v) Tween 20 and a 1-hour blocking upon 10% Donkey serum (D9663, Sigma-Aldrich) at room temperature. Cells were incubated with corresponding PBS-diluted primary antibodies protected from direct light at 4°C overnight. After three 5-minute washes with 1× PBS + 0.1% Tween 20, cells were incubated for 1 hour in PBS-diluted secondary antibodies and 15 minutes with DAPI (1:5,000; 422801, BioLegend). Cells were then washed three times with 1× PBS + 0.1% Tween for 5 minutes and once with 1× PBS. Coverslips were then fetched and mounted onto slides using Fluorescence Mounting Medium (S3023, Agilent Technologies). Slides were imaged using confocal microscope (LSM780, Zeiss).</p></sec><sec id="S26"><title>RNA-seq</title><p id="P51">Total RNA was extracted using Monarch® Total RNA Miniprep Kit (New England Biolabs, T2010S) according to the manufacturer’s instructions. RNA was quantified using NanoDrop 2000 UV Visible Spectrophotometer, while the RNA integrity was checked on Tapestation 2200 (Agilent). Only samples with RIN value above 8.0 were used for transcriptome analysis. RNA libraries were prepared using 1 μg of total RNA input using NEBNext® Poly(A) mRNA Magnetic Isolation Module, NEBNext® UltraTM II Directional RNA Library Prep Kit for Illumina® according to the manufacturer’s instructions (New England Biolabs).</p></sec><sec id="S27"><title>RNA-sequencing analysis</title><p id="P52">After removing the adapters with TrimGalore! (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</ext-link>), Kallisto was used to quantify reads mapping to each gene. Differential gene expression levels were determined using DESeq2<sup><xref ref-type="bibr" rid="R59">59</xref></sup>. All statistical analyses were performed using the latest versions of BEDTools<sup><xref ref-type="bibr" rid="R60">60</xref></sup>, deepTools<sup><xref ref-type="bibr" rid="R61">61</xref></sup>, R Studio (version 4.4.3; Trophy Case), and GraphPad Prism software version 10.2.3 (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/faq/viewfaq.cfm?faq=1362">http://www.graphpad.com/faq/viewfaq.cfm?faq=1362</ext-link>; GraphPad, San Diego, CA).</p></sec><sec id="S28"><title>CUT&amp;RUN-seq</title><p id="P53">For each condition, 1x 10<sup>5</sup> cells were processed using CUT&amp;RUN Assay Kit #86652 (Cell Signaling Technology). Briefly, each sample was resuspended in Concanavalin A Beads and treated with an Antibody Binding Buffer and the suitable antibody. After the antibody incubation, each reaction underwent a step of pAG-MNase Enzyme binding, and subsequent DNA Digestion and diffusion. The diffused DNA was then purified using Phenol/Chloroform Extraction and Ethanol Precipitation. The purified DNA was quantified using QuantiFluor dsDNA System, using the ONE dsDNA protocol (Promega). Libraries for sequencing were prepared using NEBNext Ultra II DNA Library Prep Kit for Illumina (New England BioLabs) and the libraries size distribution was assessed through automated electrophoresis using the Agilent 2200 Tapestation System (Agilent Technology).</p></sec><sec id="S29"><title>ChIP-seq</title><p id="P54">All samples from different conditions were processed together to prevent batch effects. Approximately 15 million cells were double cross-linked with 2mM disuccinimidyl glutarate (DSG) for 20 minutes followed by 1% formaldehyde for 10 minutes at room temperature, quenched with 125 mM glycine, harvested, and washed twice with 1X PBS. The fixed cell pellet was resuspended in ChIP lysis buffer (150 mM NaCl, 1% Triton X-100, 0.7% SDS, 500 μM DTT, 10 mM Tris-HCl, 5 mM EDTA) and chromatin was sheared to an average length of 200–900 base-pairs, using a Covaris S220 Ultrasonicator at 5% duty factor for 7 minutes for 3 times. The chromatin lysate was diluted with SDS-free ChIP lysis buffer. 10μg of antibody was used for BRG1. The antibody was added to at least 5μg of sonicated chromatin along with Dynabeads Protein G magnetic beads (Invitrogen) and incubated with rotation at 4°C overnight. The beads were washed twice with each of the following buffers: Mixed Micelle Buffer (150 mM NaCl, 1% Triton X- 100, 0.2% SDS, 20 mM Tris-HCl, 5 mM EDTA, 65% sucrose), Buffer 200 (200 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, 25 mM HEPES, 10 mM Tris-HCl, 1 mM EDTA), LiCl detergent wash (250 mM LiCl, 0.5% sodium deoxycholate, 0.5% NP-40, 10 mM Tris-HCl, 1 mM EDTA) and a final wash was performed with cold 0.1X TE. Finally, beads were resuspended in 1X TE containing 1% SDS and incubated at 65°C for 10 min to elute immunocomplexes. The elution was repeated twice, and the samples were incubated overnight at 65°C to reverse cross-linking, along with the input (5% of the starting material). The DNA was digested with 0.5 mg/ml Proteinase K for 3 hours at 55°C and then purified using the ChIP DNA Clean &amp; Concentrator kit (Zymo) and quantified with QUBIT. Barcoded libraries were made with NEBNext Ultra II DNA Library Prep Kit for Illumina) using NEBNext Multiplex Oligos Dual Index Primers for Illumina (New England BioLabs) and sequenced on NovaSeq X Plus instrument (Illumina).</p></sec><sec id="S30"><title>ATAC-seq</title><p id="P55">One hundred thousand cells/condition were harvested by enzymatic dissociation using StemPro™ Accutase™ (Thermo Fisher Scientific). Each cell pellet was processed using ATAC-Seq Kit (Active Motif), following the manufacturer’s directions. Briefly, the fresh cell pellets were washed in 1X PBS and lysate in ATAC Lysis Buffer. Each lysate underwent a process of tagmentation and purification, before being amplified through PCR, using the following thermal cycler parameters: 72°C for 5 min, 98°C for 30 sec, followed by 10 cycles of 98°C for 10 sec, 63°C for 30 sec, 72°C for 1 min. Each PCR reaction was cleaned up using SPRI beads (1.2X of the sample volume). The Agilent 2200 Tapestation System (Agilent Technologies) was used as quality control tool before performing next generation sequencing (NGS).</p></sec><sec id="S31"><title>Bioinformatics analysis of CHIP-seq, ATAC-seq and CUT&amp;RUN data</title><p id="P56">Adapters were removed with TrimGalore! (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</ext-link>), the sequences were aligned to the reference hg19, using Burrows-Wheeler Alignment tool, with the MEM algorithm<sup><xref ref-type="bibr" rid="R62">62</xref></sup>. Uniquely mapping aligned reads were filtered based on mapping quality (MAPQ &gt; 10) to restrict our analysis to higher quality and uniquely mapped reads, and PCR duplicates were removed. MACS2<sup><xref ref-type="bibr" rid="R63">63</xref></sup> was used to call peaks using the default parameters at 5% FDR.</p></sec><sec id="S32"><title>Motif analysis</title><p id="P57">BED files for the regions of interest were produced using BEDTools<sup><xref ref-type="bibr" rid="R60">60</xref></sup>. Motif analysis was performed using HOMER<sup><xref ref-type="bibr" rid="R57">57</xref></sup>. Shuffled input sequences were used as background. E-values &lt; 0.001 were used as a threshold for significance.</p></sec><sec id="S33"><title>Quantification and Statistical Analysis</title><p id="P58">RT-qPCR and image quantification data were analyzed using Prism software version 10.2.3 (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/faq/viewfaq.cfm?faq=1362">http://www.graphpad.com/faq/viewfaq.cfm?faq=1362</ext-link>; GraphPad, San Diego, CA). Data is represented as mean ± standard error of mean (SEM). GO enrichment analysis was performed using Webgestalt 2019<sup><xref ref-type="bibr" rid="R56">56</xref></sup>. All statistical analyses were performed using the latest versions of BEDTools<sup><xref ref-type="bibr" rid="R60">60</xref></sup>, Deeptools<sup><xref ref-type="bibr" rid="R61">61</xref></sup>, R version 4.4.3 (Throphy Case; <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link>), and Prism software version 10.2.3 (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/faq/viewfaq.cfm?faq=1362">http://www.graphpad.com/faq/viewfaq.cfm?faq=1362</ext-link>; GraphPad, San Diego, CA). In particular, Bigwigs were generated with Deeptools and normalized by sequencing depth using the same software, and upper-quantile normalized using CHIPIN<sup><xref ref-type="bibr" rid="R64">64</xref></sup>.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS206409-suppement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d38aAcGbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S34"><title>Acknowledgments</title><p>We thank the Facility for Imaging by Light Microscopy (FILM) at Imperial College London for providing access to instrumentation and technical support, which is part-supported by funding from the Wellcome Trust (grant 104931/Z/14/Z) and BBSRC (grant BB/L015129/1). We also thank the Genomics Facility at The Wistar Institute for the Next Generation Sequencing support. For this work, MT was funded by the Mathers Foundation. We thank Prof. Brian Hendrich (University of Cambridge) and Dr. Andria Koulle (Imperial College London) for insightful discussion of the data and of early versions of the manuscript.</p></ack><sec id="S35" sec-type="data-availability"><title>Data availability</title><p id="P59">RNA-seq, ATAC-seq, CUT&amp;RUN-seq, and ChIP-seq data have been deposited in the Gene Expression Omnibus (GEO) under accession code GEO: GSE293821 and are publicly available at <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293821">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293821</ext-link>.</p></sec><fn-group><fn fn-type="con" id="FN1"><p id="P60"><bold>Author Contributions</bold></p><p id="P61">MT designed the project. MD performed most of the experiments. SMB, EVD, ZHM, and LD contributed to some of the experiments. MD and MT analyzed the data and wrote the manuscript. All the authors read and approved the manuscript.</p></fn><fn fn-type="conflict" id="FN2"><p id="P62"><bold>Declaration of Interests</bold></p><p id="P63">Authors declare no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y kang</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name></person-group><article-title>Advances in understanding the regulation of pluripotency fate transition in embryonic stem cells</article-title><publisher-name>Frontiers Media SA</publisher-name><year>2024</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2024.1494398">https://doi.org/10.3389/fcell.2024.1494398</ext-link></comment><pub-id pub-id-type="pmcid">PMC11521825</pub-id><pub-id pub-id-type="pmid">39479513</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2024.1494398</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>MB</given-names></name></person-group><article-title>Stem Cell Lineages: Between Cell and Organism</article-title><source>Philosophy, Theory, and Practice in Biology</source><year>2017</year><volume>9</volume><pub-id pub-id-type="doi">10.3998/ptb.6959004.0009.006</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>ZH</given-names></name><name><surname>Sam</surname><given-names>TW</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>JJH</given-names></name><name><surname>Loh</surname><given-names>YH</given-names></name></person-group><article-title>Chromatin Regulation in Development: Current Understanding and Approaches</article-title><publisher-name>Hindawi Limited</publisher-name><year>2021</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2021/8817581">https://doi.org/10.1155/2021/8817581</ext-link></comment><pub-id pub-id-type="pmcid">PMC7872760</pub-id><pub-id pub-id-type="pmid">33603792</pub-id><pub-id pub-id-type="doi">10.1155/2021/8817581</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gopinathan</surname><given-names>G</given-names></name><name><surname>Diekwisch</surname><given-names>TGH</given-names></name></person-group><article-title>Epigenetics and Early Development</article-title><publisher-name>MDPI</publisher-name><year>2022</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/jdb10020026">https://doi.org/10.3390/jdb10020026</ext-link></comment><pub-id pub-id-type="pmcid">PMC9225096</pub-id><pub-id pub-id-type="pmid">35735917</pub-id><pub-id pub-id-type="doi">10.3390/jdb10020026</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>LD</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name></person-group><article-title>DNA methylation and its basic function</article-title><year>2013</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/npp.2012.112">https://doi.org/10.1038/npp.2012.112</ext-link></comment><pub-id pub-id-type="pmcid">PMC3521964</pub-id><pub-id pub-id-type="pmid">22781841</pub-id><pub-id pub-id-type="doi">10.1038/npp.2012.112</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>E</given-names></name></person-group><article-title>Chromatin modification and epigenetic reprogramming in mammalian development</article-title><year>2002</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg887">https://doi.org/10.1038/nrg887</ext-link></comment><pub-id pub-id-type="pmid">12209141</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>Z</given-names></name><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Naik</surname><given-names>A</given-names></name><name><surname>Eldaw</surname><given-names>M</given-names></name><name><surname>Decock</surname><given-names>J</given-names></name><name><surname>Kolatkar</surname><given-names>PR</given-names></name></person-group><article-title>Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis</article-title><publisher-name>Frontiers Media S.A</publisher-name><year>2021</year><comment>Preprint at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2021.681377">https://doi.org/10.3389/fonc.2021.681377</ext-link></comment><pub-id pub-id-type="pmcid">PMC8236851</pub-id><pub-id pub-id-type="pmid">34195082</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2021.681377</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name></person-group><article-title>Mechanisms of Interplay between Transcription Factors and the 3D Genome</article-title><publisher-name>Cell Press</publisher-name><year>2019</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molcel.2019.08.010">https://doi.org/10.1016/j.molcel.2019.08.010</ext-link></comment><pub-id pub-id-type="pmid">31521504</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>TC</given-names></name><name><surname>Hager</surname><given-names>GL</given-names></name></person-group><article-title>Dynamic regulation of transcriptional states by chromatin and transcription factors</article-title><year>2014</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg3623">https://doi.org/10.1038/nrg3623</ext-link></comment><pub-id pub-id-type="pmcid">PMC6322398</pub-id><pub-id pub-id-type="pmid">24342920</pub-id><pub-id pub-id-type="doi">10.1038/nrg3623</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tatetsu</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>NR</given-names></name><name><surname>Chong</surname><given-names>G</given-names></name><name><surname>Amabile</surname><given-names>G</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name><name><surname>Chai</surname><given-names>L</given-names></name></person-group><article-title>SALL4, the missing link between stem cells, development and cancer</article-title><publisher-name>Elsevier B.V</publisher-name><year>2016</year><comment>Preprint at., <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gene.2016.02.019">https://doi.org/10.1016/j.gene.2016.02.019</ext-link></comment><pub-id pub-id-type="pmcid">PMC4823161</pub-id><pub-id pub-id-type="pmid">26892498</pub-id><pub-id pub-id-type="doi">10.1016/j.gene.2016.02.019</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Todorova</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>NY</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>PJ</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Briggs</surname><given-names>SP</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Stemness factor Sall4 is required for DNA damage response in embryonic stem cells</article-title><source>Journal of Cell Biology</source><year>2015</year><volume>208</volume><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="pmcid">PMC4347641</pub-id><pub-id pub-id-type="pmid">25733712</pub-id><pub-id pub-id-type="doi">10.1083/jcb.201408106</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Zhen</surname><given-names>S</given-names></name><name><surname>Roumiantsev</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>LT</given-names></name><name><surname>Yuan</surname><given-names>G-C</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name></person-group><article-title>Differential Roles of Sall4 Isoforms in Embryonic Stem Cell Pluripotency</article-title><source>Mol Cell Biol</source><year>2010</year><volume>30</volume><fpage>5364</fpage><lpage>5380</lpage><pub-id pub-id-type="pmcid">PMC2976381</pub-id><pub-id pub-id-type="pmid">20837710</pub-id><pub-id pub-id-type="doi">10.1128/MCB.00419-10</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tam</surname><given-names>WL</given-names></name><name><surname>Tong</surname><given-names>GQ</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Chan</surname><given-names>HY</given-names></name><name><surname>Soh</surname><given-names>BS</given-names></name><name><surname>Lou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1</article-title><source>Nat Cell Biol</source><year>2006</year><volume>8</volume><fpage>1114</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">16980957</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis</article-title><publisher-name>BioMed Central Ltd</publisher-name><year>2018</year><comment>Preprint at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40364-017-0115-6">https://doi.org/10.1186/s40364-017-0115-6</ext-link></comment><pub-id pub-id-type="pmcid">PMC5751604</pub-id><pub-id pub-id-type="pmid">29308206</pub-id><pub-id pub-id-type="doi">10.1186/s40364-017-0115-6</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name><name><surname>Kloet</surname><given-names>SL</given-names></name><name><surname>Loos</surname><given-names>R</given-names></name><name><surname>Nishinakamura</surname><given-names>R</given-names></name><name><surname>Bertone</surname><given-names>P</given-names></name><name><surname>Vermeulen</surname><given-names>M</given-names></name><name><surname>Hendrich</surname><given-names>B</given-names></name></person-group><article-title>Sall4 controls differentiation of pluripotent cells independently of the nucleosome remodelling and deacetylation (NuRD) complex</article-title><source>Development (Cambridge)</source><year>2016</year><volume>143</volume><fpage>3074</fpage><lpage>3084</lpage><pub-id pub-id-type="pmcid">PMC5047675</pub-id><pub-id pub-id-type="pmid">27471257</pub-id><pub-id pub-id-type="doi">10.1242/dev.139113</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>N</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Chai</surname><given-names>L</given-names></name></person-group><article-title>The next new target in leukemia: The embryonic stem cell gene SALL4</article-title><source>Mol Cell Oncol</source><year>2014</year><volume>1</volume><pub-id pub-id-type="pmcid">PMC4428154</pub-id><pub-id pub-id-type="pmid">25977939</pub-id><pub-id pub-id-type="doi">10.4161/23723548.2014.969169</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuri</surname><given-names>S</given-names></name><name><surname>Fujimura</surname><given-names>S</given-names></name><name><surname>Nimura</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Toyooka</surname><given-names>Y</given-names></name><name><surname>Fujimura</surname><given-names>YI</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Ura</surname><given-names>K</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Niwa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Sall4 is essential for stabilization, but not for pluripotency, of embryonic stem cells by repressing aberrant trophectoderm gene expression</article-title><source>Stem Cells</source><year>2009</year><volume>27</volume><fpage>796</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">19350679</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>N</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>KQ</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Peterson</surname><given-names>MY</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Nishinakamura</surname><given-names>R</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sall4 regulates neuromesodermal progenitors and their descendants during body elongation in mouse embryos</article-title><source>Development (Cambridge)</source><year>2019</year><volume>146</volume><pub-id pub-id-type="pmcid">PMC6679359</pub-id><pub-id pub-id-type="pmid">31235634</pub-id><pub-id pub-id-type="doi">10.1242/dev.177659</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KQ</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Barrett</surname><given-names>J</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name></person-group><article-title>Normal embryonic development and neonatal digit regeneration in mice overexpressing a stem cell factor, Sall4</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><pub-id pub-id-type="pmcid">PMC9049339</pub-id><pub-id pub-id-type="pmid">35482646</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0267273</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>MP</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Corcoran</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>KQ</given-names></name><name><surname>Scott</surname><given-names>EP</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Gearhart</surname><given-names>MD</given-names></name><name><surname>Nishinakamura</surname><given-names>R</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name></person-group><article-title>Sall4 regulates posterior trunk mesoderm development by promoting mesodermal gene expression and repressing neural genes in the mesoderm</article-title><source>Development (Cambridge)</source><year>2024</year><volume>151</volume><pub-id pub-id-type="pmcid">PMC10946440</pub-id><pub-id pub-id-type="pmid">38345319</pub-id><pub-id pub-id-type="doi">10.1242/dev.202649</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kekunnaya</surname><given-names>R</given-names></name><name><surname>Negalur</surname><given-names>M</given-names></name></person-group><article-title>Duane retraction syndrome: Causes, effects and management strategies</article-title><publisher-name>Dove Medical Press Ltd</publisher-name><year>2017</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2147/OPTH.S127481">https://doi.org/10.2147/OPTH.S127481</ext-link></comment><pub-id pub-id-type="pmcid">PMC5669793</pub-id><pub-id pub-id-type="pmid">29133973</pub-id><pub-id pub-id-type="doi">10.2147/OPTH.S127481</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terhal</surname><given-names>P</given-names></name><name><surname>Rösler</surname><given-names>B</given-names></name><name><surname>Kohlhase</surname><given-names>J</given-names></name></person-group><article-title>A family with features overlapping Okihiro syndrome, hemifacial microsomia and isolated Duane anomaly caused by a novel SALL4 mutation</article-title><source>Am J Med Genet</source><year>2006</year><volume>140 A</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">16411190</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Carroll</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>HR</given-names></name><name><surname>Silberstein</surname><given-names>LE</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>L</given-names></name></person-group><article-title>Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><pub-id pub-id-type="pmcid">PMC2679146</pub-id><pub-id pub-id-type="pmid">19440552</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005577</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Tate</surname><given-names>P</given-names></name><name><surname>Pardo</surname><given-names>M</given-names></name><name><surname>Choudhary</surname><given-names>J</given-names></name></person-group><article-title>Characterization of two distinct nucleosome remodeling and deacetylase (NuRD) complex assemblies in embryonic stem cells</article-title><source>Molecular and Cellular Proteomics</source><year>2016</year><volume>15</volume><fpage>878</fpage><lpage>891</lpage><pub-id pub-id-type="pmcid">PMC4813707</pub-id><pub-id pub-id-type="pmid">26714524</pub-id><pub-id pub-id-type="doi">10.1074/mcp.M115.053207</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>BH</given-names></name><name><surname>Jobichen</surname><given-names>C</given-names></name><name><surname>Chia</surname><given-names>CSB</given-names></name><name><surname>Chan</surname><given-names>THM</given-names></name><name><surname>Tang</surname><given-names>JP</given-names></name><name><surname>Chung</surname><given-names>TXY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Poulsen</surname><given-names>A</given-names></name><name><surname>Hung</surname><given-names>AW</given-names></name><name><surname>Koh-Stenta</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>E7119</fpage><lpage>E7128</lpage><pub-id pub-id-type="pmcid">PMC6065023</pub-id><pub-id pub-id-type="pmid">29976840</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1801253115</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ming</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Kuang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><etal/></person-group><article-title>The NuRD complex cooperates with SALL4 to orchestrate reprogramming</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><pub-id pub-id-type="pmcid">PMC10199099</pub-id><pub-id pub-id-type="pmid">37208322</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-38543-0</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliaroli</surname><given-names>L</given-names></name><name><surname>Porazzi</surname><given-names>P</given-names></name><name><surname>Curtis</surname><given-names>AT</given-names></name><name><surname>Scopa</surname><given-names>C</given-names></name><name><surname>Mikkers</surname><given-names>HMM</given-names></name><name><surname>Freund</surname><given-names>C</given-names></name><name><surname>Daxinger</surname><given-names>L</given-names></name><name><surname>Deliard</surname><given-names>S</given-names></name><name><surname>Welsh</surname><given-names>SA</given-names></name><name><surname>Offley</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disorders</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC8578637</pub-id><pub-id pub-id-type="pmid">34753942</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-26810-x</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajpai</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>DA</given-names></name><name><surname>Rada-Iglesias</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Helms</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>CP</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Swigut</surname><given-names>T</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><article-title>CHD7 cooperates with PBAF to control multipotent neural crest formation</article-title><source>Nature</source><year>2010</year><volume>463</volume><fpage>958</fpage><lpage>962</lpage><pub-id pub-id-type="pmcid">PMC2890258</pub-id><pub-id pub-id-type="pmid">20130577</pub-id><pub-id pub-id-type="doi">10.1038/nature08733</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnada</surname><given-names>SM</given-names></name><name><surname>de Gracia</surname><given-names>Giner</given-names></name><name><surname>Morenilla-Palao</surname><given-names>C</given-names></name><name><surname>López-Cascales</surname><given-names>MT</given-names></name><name><surname>Scopa</surname><given-names>C</given-names></name><name><surname>Waltrich</surname><given-names>FJ</given-names></name><name><surname>Mikkers</surname><given-names>HMM</given-names></name><name><surname>Cicardi</surname><given-names>ME</given-names></name><name><surname>Karlin</surname><given-names>J</given-names></name><name><surname>Trotti</surname><given-names>D</given-names></name><etal/></person-group><article-title>ARID1A-BAF coordinates ZIC2 genomic occupancy for epithelial-to-mesenchymal transition in cranial neural crest specification</article-title><source>The American Journal of Human Genetics</source><year>2024</year><pub-id pub-id-type="pmcid">PMC11480806</pub-id><pub-id pub-id-type="pmid">39226899</pub-id><pub-id pub-id-type="doi">10.1016/j.ajhg.2024.07.022</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>ZH</given-names></name><name><surname>den Hoed</surname><given-names>J</given-names></name><name><surname>Claassen</surname><given-names>W</given-names></name><name><surname>Demurtas</surname><given-names>M</given-names></name><name><surname>Deelen</surname><given-names>L</given-names></name><name><surname>Campeau</surname><given-names>PM</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Fisher</surname><given-names>SE</given-names></name><name><surname>Trizzino</surname><given-names>M</given-names></name></person-group><article-title>CHD3 regulates BMP signalling response during cranial neural crest cell specification</article-title><year>2025</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2025.02.14.638260">https://doi.org/10.1101/2025.02.14.638260</ext-link></comment><pub-id pub-id-type="doi">10.1101/2025.02.14.638260</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prescott</surname><given-names>SL</given-names></name><name><surname>Srinivasan</surname><given-names>R</given-names></name><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Grishina</surname><given-names>I</given-names></name><name><surname>Narvaiza</surname><given-names>I</given-names></name><name><surname>Selleri</surname><given-names>L</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Swigut</surname><given-names>T</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><article-title>Enhancer Divergence and cis-Regulatory Evolution in the Human and Chimp Neural Crest</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>68</fpage><lpage>83</lpage><pub-id pub-id-type="pmcid">PMC4848043</pub-id><pub-id pub-id-type="pmid">26365491</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.036</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname><given-names>C</given-names></name><name><surname>Kirkland</surname><given-names>JG</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name></person-group><article-title>The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer</article-title><source>Cold Spring Harb Perspect Med</source><year>2016</year><volume>6</volume><pub-id pub-id-type="pmcid">PMC4968166</pub-id><pub-id pub-id-type="pmid">27413115</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026930</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name></person-group><article-title>BAF Complex in Embryonic Stem Cells and Early Embryonic Development</article-title><publisher-name>Hindawi Limited</publisher-name><year>2021</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2021/6668866">https://doi.org/10.1155/2021/6668866</ext-link></comment><pub-id pub-id-type="pmcid">PMC7826211</pub-id><pub-id pub-id-type="pmid">33510794</pub-id><pub-id pub-id-type="doi">10.1155/2021/6668866</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="pmcid">PMC8371605</pub-id><pub-id pub-id-type="pmid">34265844</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Chronis</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Spalinskas</surname><given-names>R</given-names></name><name><surname>Pardo</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The BAF and PRC2 Complex Subunits Dpf2 and Eed Antagonistically Converge on Tbx3 to Control ESC Differentiation</article-title><source>Cell Stem Cell</source><year>2019</year><volume>24</volume><fpage>138</fpage><lpage>152</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC6486830</pub-id><pub-id pub-id-type="pmid">30609396</pub-id><pub-id pub-id-type="doi">10.1016/j.stem.2018.12.001</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasteva</surname><given-names>V</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name><name><surname>Lessard</surname><given-names>JA</given-names></name></person-group><article-title>The BAF45a/PHF10 subunit of SWI/SNF-like chromatin remodeling complexes is essential for hematopoietic stem cell maintenance</article-title><source>Exp Hematol</source><year>2017</year><volume>48</volume><fpage>58</fpage><lpage>71</lpage><elocation-id>e15</elocation-id><pub-id pub-id-type="pmcid">PMC11975438</pub-id><pub-id pub-id-type="pmid">27931852</pub-id><pub-id pub-id-type="doi">10.1016/j.exphem.2016.11.008</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessard</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>JI</given-names></name><name><surname>Ranish</surname><given-names>JA</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Winslow</surname><given-names>MM</given-names></name><name><surname>Staahl</surname><given-names>BT</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Aebersold</surname><given-names>R</given-names></name><name><surname>Graef</surname><given-names>IA</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name></person-group><article-title>An Essential Switch in Subunit Composition of a Chromatin Remodeling Complex during Neural Development</article-title><source>Neuron</source><year>2007</year><volume>55</volume><fpage>201</fpage><lpage>215</lpage><pub-id pub-id-type="pmcid">PMC2674110</pub-id><pub-id pub-id-type="pmid">17640523</pub-id><pub-id pub-id-type="doi">10.1016/j.neuron.2007.06.019</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazim</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Feng</surname><given-names>AC</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Yeom</surname><given-names>KH</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Daly</surname><given-names>AE</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Vu</surname><given-names>H</given-names></name><name><surname>Ernst</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alternative splicing of a chromatin modifier alters the transcriptional regulatory programs of stem cell maintenance and neuronal differentiation</article-title><source>Cell Stem Cell</source><year>2024</year><volume>31</volume><fpage>754</fpage><lpage>771</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmcid">PMC11126784</pub-id><pub-id pub-id-type="pmid">38701759</pub-id><pub-id pub-id-type="doi">10.1016/j.stem.2024.04.001</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rgen Kohlhase</surname><given-names>J</given-names></name><name><surname>Heinrich</surname><given-names>M</given-names></name><name><surname>Schubert</surname><given-names>L</given-names></name><name><surname>Liebers</surname><given-names>M</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Laccone</surname><given-names>F</given-names></name><name><surname>Turnpenny</surname><given-names>P</given-names></name><name><surname>Winter</surname><given-names>RM</given-names></name><name><surname>Reardon</surname><given-names>W</given-names></name></person-group><article-title>Okihiro syndrome is caused by SALL4 mutations</article-title><publisher-name>Oxford University Press</publisher-name><year>2002</year><volume>11</volume><fpage>2979</fpage><lpage>2987</lpage><pub-id pub-id-type="pmid">12393809</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Baradie</surname><given-names>R</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>St Hilaire</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Andrews</surname><given-names>C</given-names></name><name><surname>McIntosh</surname><given-names>N</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Jean Martonyi</surname><given-names>E</given-names></name><name><surname>Raymond</surname><given-names>WR</given-names></name><name><surname>Okumura</surname><given-names>S</given-names></name><etal/></person-group><article-title>Duane Radial Ray Syndrome (Okihiro Syndrome) Maps to 20q13 and Results from Mutations in SALL4, a New Member of the SAL Family</article-title><year>2002</year><pub-id pub-id-type="pmcid">PMC385096</pub-id><pub-id pub-id-type="pmid">12395297</pub-id><pub-id pub-id-type="doi">10.1086/343821</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>van der Watt</surname><given-names>PJ</given-names></name><name><surname>Kay</surname><given-names>SA</given-names></name></person-group><article-title>E-box binding transcription factors in cancer</article-title><publisher-name>Frontiers Media SA</publisher-name><year>2023</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2023.1223208">https://doi.org/10.3389/fonc.2023.1223208</ext-link></comment><pub-id pub-id-type="pmcid">PMC10437117</pub-id><pub-id pub-id-type="pmid">37601651</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1223208</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Ovol2 induces mesenchymal–epithelial transition via targeting ZEB1 in osteosarcoma</article-title><source>Onco Targets Ther</source><year>2018</year><volume>11</volume><fpage>2963</fpage><lpage>2973</lpage><pub-id pub-id-type="pmcid">PMC5973319</pub-id><pub-id pub-id-type="pmid">29872308</pub-id><pub-id pub-id-type="doi">10.2147/OTT.S157119</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haensel</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>MacLean</surname><given-names>AL</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Stemmler</surname><given-names>MP</given-names></name><name><surname>Brabletz</surname><given-names>S</given-names></name><name><surname>Berx</surname><given-names>G</given-names></name><name><surname>Plikus</surname><given-names>MV</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><etal/></person-group><article-title>An Ovol2-Zeb1 transcriptional circuit regulates epithelial directional migration and proliferation</article-title><source>EMBO Rep</source><year>2019</year><volume>20</volume><pub-id pub-id-type="pmcid">PMC6322385</pub-id><pub-id pub-id-type="pmid">30413481</pub-id><pub-id pub-id-type="doi">10.15252/embr.201846273</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kodytková</surname><given-names>A</given-names></name><name><surname>Dušátková</surname><given-names>P</given-names></name><name><surname>Anne Amaratunga</surname><given-names>S</given-names></name><name><surname>Plachý</surname><given-names>L</given-names></name><name><surname>Pruhová</surname><given-names>Š</given-names></name><name><surname>Lebl</surname><given-names>J</given-names></name></person-group><article-title>Integrative role of the sall4 gene: From thalidomide embryopathy to genetic defects of the upper limb, internal organs, cerebral midline, and pituitary</article-title><publisher-name>S. Karger AG</publisher-name><year>2023</year><comment>Preprint at, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000531452">https://doi.org/10.1159/000531452</ext-link></comment><pub-id pub-id-type="pmcid">PMC11008716</pub-id><pub-id pub-id-type="pmid">37285827</pub-id><pub-id pub-id-type="doi">10.1159/000531452</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MT</given-names></name></person-group><article-title>Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus</article-title><source>Transaction of the American Ophtalmological Society</source><year>1991</year><fpage>623</fpage><lpage>674</lpage><pub-id pub-id-type="pmcid">PMC1298636</pub-id><pub-id pub-id-type="pmid">1808819</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlhase</surname><given-names>J</given-names></name><name><surname>Chitayat</surname><given-names>D</given-names></name><name><surname>Kotzot</surname><given-names>D</given-names></name><name><surname>Ceylaner</surname><given-names>S</given-names></name><name><surname>Froster</surname><given-names>UG</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Montgomery</surname><given-names>T</given-names></name><name><surname>Rösler</surname><given-names>B</given-names></name></person-group><article-title>SALL4 mutations in Okihiro syndrome (Duane-radial ray syndrome), acro-renal-ocular syndrome, and related disorders</article-title><year>2005</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/humu.20215">https://doi.org/10.1002/humu.20215</ext-link></comment><pub-id pub-id-type="pmid">16086360</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlhase</surname><given-names>J</given-names></name><name><surname>Chitayat</surname><given-names>D</given-names></name><name><surname>Kotzot</surname><given-names>D</given-names></name><name><surname>Ceylaner</surname><given-names>S</given-names></name><name><surname>Froster</surname><given-names>UG</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Montgomery</surname><given-names>T</given-names></name><name><surname>Rösler</surname><given-names>B</given-names></name></person-group><article-title>SALL4 mutations in Okihiro syndrome (Duane-radial ray syndrome), acro-renal-ocular syndrome, and related disorders</article-title><year>2005</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/humu.20215">https://doi.org/10.1002/humu.20215</ext-link></comment><pub-id pub-id-type="doi">10.1002/humu.20215</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>A proteomic approach identifies SAFB-like transcription modulator (SLTM) as a bidirectional regulator of GLI family zinc finger transcription factors</article-title><source>Journal of Biological Chemistry</source><year>2019</year><volume>294</volume><fpage>5549</fpage><lpage>5561</lpage><pub-id pub-id-type="pmcid">PMC6462520</pub-id><pub-id pub-id-type="pmid">30782847</pub-id><pub-id pub-id-type="doi">10.1074/jbc.RA118.007018</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>NR</given-names></name><name><surname>Bassal</surname><given-names>MA</given-names></name><name><surname>Tan</surname><given-names>HK</given-names></name><name><surname>Kurland</surname><given-names>JV</given-names></name><name><surname>Yong</surname><given-names>KJ</given-names></name><name><surname>Young</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>JD</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Zinc Finger Protein SALL4 Functions through an AT-Rich Motif to Regulate Gene Expression</article-title><source>Cell Rep</source><year>2021</year><volume>34</volume><pub-id pub-id-type="pmcid">PMC8197658</pub-id><pub-id pub-id-type="pmid">33406418</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108574</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantier</surname><given-names>R</given-names></name><name><surname>Chhatbar</surname><given-names>K</given-names></name><name><surname>Quante</surname><given-names>T</given-names></name><name><surname>Skourti-Stathaki</surname><given-names>K</given-names></name><name><surname>Cholewa-Waclaw</surname><given-names>J</given-names></name><name><surname>Alston</surname><given-names>G</given-names></name><name><surname>Alexander-Howden</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Cook</surname><given-names>AG</given-names></name><name><surname>Spruijt</surname><given-names>CG</given-names></name><etal/></person-group><article-title>SALL4 controls cell fate in response to DNA base composition</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>845</fpage><lpage>858</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC7895904</pub-id><pub-id pub-id-type="pmid">33406384</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2020.11.046</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borozdin</surname><given-names>W</given-names></name><name><surname>Boehm</surname><given-names>D</given-names></name><name><surname>Leipoldt</surname><given-names>M</given-names></name><name><surname>Wilhelm</surname><given-names>C</given-names></name><name><surname>Reardon</surname><given-names>W</given-names></name><name><surname>Clayton-Smith</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Mühlendyck</surname><given-names>H</given-names></name><name><surname>Winter</surname><given-names>R</given-names></name><name><surname>Giray</surname><given-names>O</given-names></name><etal/></person-group><article-title>SALL4 deletions are a common cause of Okihiro and acro-renal-ocular syndromes and confirm haploinsufficiency as the pathogenic mechanism</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><pub-id pub-id-type="pmcid">PMC1735888</pub-id><pub-id pub-id-type="pmid">15342710</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.019901</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>A de novo mutation of SALL4 in a Chinese family with Okihiro syndrome</article-title><source>Mol Med Rep</source><year>2022</year><volume>25</volume><pub-id pub-id-type="pmcid">PMC8867470</pub-id><pub-id pub-id-type="pmid">35179219</pub-id><pub-id pub-id-type="doi">10.3892/mmr.2022.12647</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>KA</given-names></name><name><surname>A</surname><given-names>J</given-names></name><name><surname>N</surname><given-names>R</given-names></name><name><surname>Y</surname><given-names>J</given-names></name><name><surname>F</surname><given-names>E</given-names></name><name><surname>B</surname><given-names>B</given-names></name><name><surname>E</surname><given-names>B</given-names></name><name><surname>F</surname><given-names>E</given-names></name></person-group><article-title>Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome</article-title><year>2018</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7554/eLife.38430.001">https://doi.org/10.7554/eLife.38430.001</ext-link></comment><pub-id pub-id-type="pmcid">PMC6156078</pub-id><pub-id pub-id-type="pmid">30067223</pub-id><pub-id pub-id-type="doi">10.7554/eLife.38430</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matyskiela</surname><given-names>ME</given-names></name><name><surname>Couto</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Stamp</surname><given-names>K</given-names></name><name><surname>Drew</surname><given-names>C</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Carpenter</surname><given-names>A</given-names></name><etal/></person-group><article-title>SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate</article-title><source>Nat Chem Biol</source><year>2018</year><volume>14</volume><fpage>981</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">30190590</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anh Vu</surname><given-names>KL</given-names></name><name><surname>Kumari</surname><given-names>K</given-names></name><name><surname>Hui Liu</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ping Tang</surname><given-names>J</given-names></name><name><surname>Maddalo</surname><given-names>D</given-names></name><name><surname>Auld</surname><given-names>DS</given-names></name><name><surname>Casalena</surname><given-names>DE</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><etal/></person-group><article-title>SALL4B, not targeted by IMiD, is important for SALL4-mediated tumorigenesis</article-title><year>2023</year><pub-id pub-id-type="doi">10.1101/2023.07.07.548071</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jaehnig</surname><given-names>EJ</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>W199</fpage><lpage>W205</lpage><pub-id pub-id-type="pmcid">PMC6602449</pub-id><pub-id pub-id-type="pmid">31114916</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz401</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname><given-names>S</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Spann</surname><given-names>N</given-names></name><name><surname>Bertolino</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Laslo</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>JX</given-names></name><name><surname>Murre</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><article-title>Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities</article-title><source>Mol Cell</source><year>2010</year><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="pmcid">PMC2898526</pub-id><pub-id pub-id-type="pmid">20513432</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><etal/></person-group><article-title>Fiji: An open-source platform for biological-image analysis</article-title><year>2012</year><comment>Preprint, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nmeth.2019">https://doi.org/10.1038/nmeth.2019</ext-link></comment><pub-id pub-id-type="pmcid">PMC3855844</pub-id><pub-id pub-id-type="pmid">22743772</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><pub-id pub-id-type="pmcid">PMC4302049</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><article-title>BEDTools: A flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="pmcid">PMC2832824</pub-id><pub-id pub-id-type="pmid">20110278</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez</surname><given-names>F</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Grüning</surname><given-names>B</given-names></name><name><surname>Bhardwaj</surname><given-names>V</given-names></name><name><surname>Kilpert</surname><given-names>F</given-names></name><name><surname>Richter</surname><given-names>AS</given-names></name><name><surname>Heyne</surname><given-names>S</given-names></name><name><surname>Dündar</surname><given-names>F</given-names></name><name><surname>Manke</surname><given-names>T</given-names></name></person-group><article-title>deepTools2: a next generation web server for deep-sequencing data analysis</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>W160</fpage><lpage>W165</lpage><pub-id pub-id-type="pmcid">PMC4987876</pub-id><pub-id pub-id-type="pmid">27079975</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkw257</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbreteau</surname><given-names>G</given-names></name><name><surname>Airaud</surname><given-names>F</given-names></name><name><surname>Pierre-Noël</surname><given-names>E</given-names></name><name><surname>Vallée</surname><given-names>A</given-names></name><name><surname>Bézieau</surname><given-names>S</given-names></name><name><surname>Théoleyre</surname><given-names>S</given-names></name><name><surname>Blons</surname><given-names>H</given-names></name><name><surname>Garinet</surname><given-names>S</given-names></name><name><surname>Denis</surname><given-names>MG</given-names></name></person-group><article-title>MEM: An algorithm for the reliable detection of microsatellite instability (MSI) on a small NGS panel in colorectal cancer</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><pub-id pub-id-type="pmcid">PMC8394433</pub-id><pub-id pub-id-type="pmid">34439357</pub-id><pub-id pub-id-type="doi">10.3390/cancers13164203</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Nussbaum</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Model-based analysis of ChIP-Seq (MACS</article-title><source>Genome Biol</source><year>2008</year><volume>9</volume><pub-id pub-id-type="pmcid">PMC2592715</pub-id><pub-id pub-id-type="pmid">18798982</pub-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polit</surname><given-names>L</given-names></name><name><surname>Kerdivel</surname><given-names>G</given-names></name><name><surname>Gregoricchio</surname><given-names>S</given-names></name><name><surname>Esposito</surname><given-names>M</given-names></name><name><surname>Guillouf</surname><given-names>C</given-names></name><name><surname>Boeva</surname><given-names>V</given-names></name></person-group><article-title>CHIPIN: ChIP-seq inter-sample normalization based on signal invariance across transcriptionally constant genes</article-title><source>BMC Bioinformatics</source><year>2021</year><volume>22</volume><pub-id pub-id-type="pmcid">PMC8371782</pub-id><pub-id pub-id-type="pmid">34404353</pub-id><pub-id pub-id-type="doi">10.1186/s12859-021-04320-3</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>SALL4A interacts with the BAF complex through DPF2.</title><p>(A) Immunoblot of nuclear protein (5% input) and co-immunoprecipitations (co-IP) of ARID1B and IgG (negative control) from <italic>SALL4</italic>-WT cells at Day-5.</p><p>(B) (Left) AlphaFold structure model showing the predicted interactions between SALL4A (red), DPF2 (dark blue), and other BAF components, including SMARCA4, SMARCB1, and ACTL6A. (Center) Visual representation of the confidence score (predicted Local Distance Difference Test - pLDDT) for each residue of the AlphaFold-predicted complex, with color gradients indicating prediction confidence (blue: very high confidence, yellow: low confidence, orange/red: very low confidence). (Right) Close-up view of the SALL4A-DPF2 interface highlighting key interacting residues in red.</p><p>(C) SALL4A and SALL4B protein sequences. C2H2 zinc fingers annotations are highlighted in dark purple and numbered. Visual representation of output models of SALL4A (model 0) and SALL4B (models 1, 3, and 4). Predicted interactions between SALL4 isoforms and DPF2 are highlighted in different colors in each model. SALL4A is predicted to interact with DPF2 through the ZFs 4, 5 and 6 (ZFC3) and 7 (ZFC4), light purple. Made with BioRender.com.</p><p>(D) Zoomed view of SALL4 (pink) and DPF2 (purple) interacting surfaces. Highlighted are the functional domains involved in the predicted interaction (ZF6 and ZF7 of SALL4 and PHD1 and PHD2 of DPF2). In red, contacts predicted by AlphaFold<sup><xref ref-type="bibr" rid="R34">34</xref></sup>.</p><p>(E) Violin plots displaying expression (log2[TPM]) of the four members of the DPF protein family (<italic>PHF10, DPF1</italic>, and <italic>DPF3</italic>) in iPSCs (left), neuroectodermal-like cells (Day-5 – center), and in CNCCs (Day-14 – right). Differences between conditions were assessed using unpaired student’s t-test.</p></caption><graphic xlink:href="EMS206409-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Generation of a <italic>SALL4</italic>-haploinsufficient human iPSC line</title><p>(A) Visual representation of the CRISPR/Cas9 approach used on the <italic>SALL4</italic> gene model. The star represents the exact location of the deletion generated by Cas9. Sanger sequencing confirming the 19 bp deletion in one allele of <italic>SALL4</italic> is displayed. Made with BioRender.com.</p><p>(B) Immunoblot for SALL4 in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO iPSC lines. GAPDH was used as a loading control.</p><p>(C) Violin plots displaying expression (log2[TPM]) of the <italic>SALL4</italic> paralogues (<italic>SALL1, SALL2, SALL3</italic>) in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO iPSCs. Statistical significance was assessed using unpaired student’s t-test.</p><p>(D) Immunoblot for SALL1 in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO iPSC lines. GAPDH was used as a loading control.</p><p>(E) Growth curve comparing <italic>SALL4</italic>-WT with <italic>SALL4</italic>-het-KO iPSC lines. N = 2 biologically independent experiments. Error bars display standard error of the mean.</p><p>(F) Morphology of <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO iPSC colonies at 4x (top) and 10x (bottom).</p></caption><graphic xlink:href="EMS206409-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Stem cell identity is unaffected by SALL4 loss</title><p>(A) (Left) Immunofluorescence labeling quantifying the expression of the canonical pluripotency markers OCT4 and NANOG in the two iPSC lines. Scale bar: 50 μm. (Right) Corrected Total Cell Fluorescence (CTCF) values were used to quantify and compare markers expression.</p><p>(B) Flow cytometry quantifying the expression of surface markers for pluripotency (TRA-60-1-R and SSEA-4).</p><p>(C) Volcano plot of genes differentially expressed in <italic>SALL4</italic>-het-KO relative to <italic>SALL4</italic>-WT in iPSCs (Day-0). Blue dots (n= 50) represent downregulated genes with p-adj &lt; 0.05 and log2FoldChange &lt; -1.5. Purple dots (n= 63) represent upregulated genes with p-adj &lt; 0.05 and log2FoldChange &gt; 1.5.</p><p>(D) Top 10 GO term enrichment for downregulated genes in <italic>SALL4</italic>-het-KO iPSCs determined using WebGestalt<sup><xref ref-type="bibr" rid="R56">56</xref></sup> over-representation pathway analysis, using affinity propagation as parameter for redundancy removal. In bold terms with FDR &lt; 0.05).</p><p>(E) Top 10 GO term enrichment for upregulated genes in <italic>SALL4</italic>-het-KO iPSCs determined using WebGestalt<sup><xref ref-type="bibr" rid="R56">56</xref></sup> over-representation pathway analysis, using affinity propagation as parameter for redundancy removal. All terms are non-significant (FDR &gt; 0.05).</p></caption><graphic xlink:href="EMS206409-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>SALL4 relocates to CNCC enhancers to induce chromatin accessibility</title><p>(A) Schematic representation of the iPSC-to-CNCC differentiation protocol. The experimental timeline shows in vitro differentiation of iPSCs into cranial neural crest cells (CNCCs) via a neuroectodermal-like stage. Cells were maintained in pluripotency self-renewing conditions until Day-0, transitioned into differentiation medium starting at Day-0 and further to maintenance medium at ~ Day-7/8. Key analyses were performed at Day-0, Day-5, and Day-14.</p><p>(B) Heatmaps showing the distribution of SALL4 binding at Day-0 and Day-5 across Day-0 specific (left) and Day-5 specific (right) binding regions.</p><p>(C) Genomic distribution of SALL4 binding sites relative to the nearest transcription start site (TSS). Peaks are categorized by distance into six bins: &lt;1 kb, 1–3 kb, 3–5 kb, 5–10 kb, 10–100 kb, and &gt;100 kb. Peaks located at &gt;1kb from the nearest TSS were classified as putative enhancers.</p><p>(D) Gene ontology analysis of Day-5 specific SALL4-bound regions as determined using WebGestalt<sup><xref ref-type="bibr" rid="R56">56</xref></sup> over-representation pathway analysis, using affinity propagation as parameter for redundancy removal (FDR&lt;0.05).</p><p>(E) Table of motifs enriched in Day-5 specific SALL4-bound regions as determined using HOMER<sup><xref ref-type="bibr" rid="R57">57</xref></sup>.</p><p>(F) Heatmaps showing ATAC-seq signals at Day-0 (left) and Day-5 (right), at Day-5 specific SALL4 CUT&amp;RUN peaks. Each row represents an individual peak. Signal intensity is color-coded, with higher intensity indicating higher chromatin accessibility.</p><p>(G) Average profiles showing ATAC-seq signal at Day 5-specific SALL4 CUT&amp;RUN peaks in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO cells in two distinct biological replicates.</p></caption><graphic xlink:href="EMS206409-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>SALL4 recruits BAF to CNCC enhancers.</title><p>(A) Heatmap and average profiles show BRG1 ChIP-seq signal at the SALL4 Day-5 specific CUT&amp;RUN peaks (n = 17,137).</p><p>(B) Heatmap and average profiles show SALL4 CUT&amp;RUN signal at the genomic sites that lose BRG1 in <italic>SALL4</italic>-het-KO cells at Day-0 and Day-5 (n = 13,505).</p><p>(C) Heatmap and average profiles show BRG1 ChIP-seq signal at the genomic sites that lose BRG1 in <italic>SALL4</italic>-het-KO cells at day 5 (n = 13,505).</p><p>(D) ATAC-seq signal at the genomic sites that lose BRG1 in <italic>SALL4</italic>-het-KO cells (n = 13,505).</p><p>(E) and (F) GO term enrichment for genes near BRG1 ChIP-seq peaks lost (E) and gained (F) in <italic>SALL4</italic>-het-KO cells. GO terms were determined using WebGestalt<sup><xref ref-type="bibr" rid="R56">56</xref></sup> over-representation pathway analysis, using affinity propagation as parameter for redundancy removal (FDR&lt;0.05).</p></caption><graphic xlink:href="EMS206409-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>CNCC induction and specification are impaired in <italic>SALL4</italic>-het-KO.</title><p>(A) Box plot displaying relative mRNA expression of canonical CNCC markers in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO cells at Day-14. Statistical significance was assessed using unpaired student’s t-test. 18S rRNA was used to normalize samples.</p><p>(B) Flow cytometry for the CNCC surface marker CD99 in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO CNCCs at Day-14.</p><p>(C) Volcano plot of genes differentially expressed in <italic>SALL4</italic>-het-KO relative to <italic>SALL4</italic>-WT in CNCCs (Day-14). Blue dots (n= 659) represent downregulated genes with p-adj &lt; 0.05 and log2FoldChange &lt; -1.5. Purple dots (n= 447) represent upregulated genes with p-adj &lt; 0.05 and log2FoldChange &gt; 1.5.</p><p>(D) GO term enrichment for downregulated genes in <italic>SALL4</italic>-het-KO cells determined using WebGestalt<sup><xref ref-type="bibr" rid="R56">56</xref></sup> over-representation pathway analysis, using affinity propagation as parameter for redundancy removal (FDR &lt; 0.05).</p><p>(E) Heatmap displaying the expression of canonical epithelial-to-mesenchymal transition (EMT) markers in <italic>SALL4</italic>-WT and <italic>SALL4</italic>-het-KO.</p><p>(F), (G), (H), and (I). Trajectory of stage-specific markers at Day-0, Day-5, and Day-14. Displayed are the medians of normalized expression (log2[TPMs]) for (F) pluripotency (<italic>POU5F1</italic> and <italic>NANOG</italic>), (G) neural plate border (NPB; <italic>ZIC1, GBX2, MSX1, MSX2, PAX3, PAX7, DLX5, DLX6, GATA2, GATA3</italic>), (H) CNCC specification (<italic>SNAI1, SNAI2, SOX9, TFAP2A</italic>), and (I) post-migratory CNCC (<italic>SOX5, SOX6, SOX10</italic>) markers at each time-point. Dotted lines represent simple linear regression.</p></caption><graphic xlink:href="EMS206409-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>Working model.</title><p>In wild-type conditions, SALL4 recruits BAF at neural crest induction enhancers. This activates lineage specific gene expression, allowing for NCC induction and specification. In the absence of SALL4, the NCC induction enhancers remain repressed because BAF is not loaded at chromatin, and the NCC gene program is not launched, and NCC induction is aborted.</p></caption><graphic xlink:href="EMS206409-f007"/></fig></floats-group></article>